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ABSTRACT 
 
Melissa Champlin Caughey:  Is sickle cell trait a risk factor for stroke and cerebral small vessel 
disease? 
(Under the direction of Laura Loehr and Kari North) 
 
 
We have recently shown an association between sickle cell trait (SCT) and ischemic stroke in the 
Atherosclerosis Risk in Communities (ARIC) study.  The etiology of stroke in this population is 
unclear, however.  Though not considered a hematological disorder, the SCT phenotype is 
nonetheless associated with hypercoagulability, vasculopathy, and possibly hypoperfusion.  To 
further understand the cerebrovascular pathophysiology, we examined a subset of African 
Americans in the ARIC study (N=844, mean age=62, female=64%) who were prospectively 
imaged by cerebral MRI in 1993-1995, and 470 (56%) who returned for a follow up MRI in 
2004-2006.  White matter lesions (WML) and subclinical brain infarctions (SBI) in participants 
with no prior history of stroke were detected by cerebral MRI.  Associations between SCT and 
WML prevalence and severity were analyzed using ordinal logistic and linear regression.  
Similarly, associations between SCT and the prevalence and progression of SBI were analyzed 
using logistic regression.  Models were adjusted for age, sex, cerebrovascular risk factors, and 10 
principal components of ancestry. SCT was identified in 56 (6.6%) participants at the first MRI.  
Individuals with SCT had more prevalent (86% vs. 79%), and more severe (mean score 1.5 vs. 
1.3) WML than individuals without SCT. SCT was also associated with a 20% increased odds of 
WML prevalence (POR 1.2, 95% CI: 0.7 – 2.0), and an adjusted mean severity score that was 0.2 
(-0.1 – 0.5) points higher; however neither of these estimates was statistically significant.  
Likewise, SCT was not associated with prevalent SBI (POR = 0.7; 95% CI: 0.3 – 1.8), or 
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incidence of new infarctions by the follow up exam (OR = 1.4; 95% CI: 0.6 – 3.1).  In 
conclusion, we observed no statistically significant associations between SCT and cerebral small 
vessel disease.  There was a trend for greater WML prevalence and severity among those with 
SCT, as well as a higher 11-year incidence of SBI; however, the estimates were imprecise and 
inconclusive.   
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CHAPTER 1:  LITERATURE REVIEW 
1. INTRODUCTION 
 African Americans are disproportionately burdened by stroke, a leading cause of 
disability and death in the United States.  We hypothesize that sickle cell trait is a genetic risk 
factor cerebrovascular disease in African Americans.  The following literature review will 
describe the genetics and pathophysiology of sickle cell trait, and its associations with 
hypercoagulability and vasculopathy.  Following this, the pathophysiology and epidemiology 
of stroke, subclinical brain infarctions, and white matter lesions will be described, 
highlighting the genetic risk factors and etiological associations with thrombosis and 
vasculopathy.  We will conclude by summarizing observational studies of sickle cell trait and 
stroke, and the public health implications of the hypothesized association. 
2.  SICKLE CELL TRAIT 
2.1 Overview 
 Sickle cell trait (SCT) is the heterozygous form of sickle cell anemia (SCA), a 
Mendelian hemoglobinopathy characterized by misshapen red blood cells, acute chest 
syndrome, and vaso-occlusive crises1.   Unlike sickle cell anemia, SCT is generally 
considered a benign carrier state, rather than a disease1.  However, under certain conditions, 
the erythrocytes of SCT carriers are known to sickle, impeding blood flow through the 
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microcirculation and increasing coagulation.  The expression of SCT is influenced by several 
genetic factors and the coinheritance of other hemoglobinopathies, as described below. 
2.2 The Sickle Mutation 
 Adult hemoglobin consists of 2 α-globin chains, 2 β-globin chains, and 4 heme 
groups, which bind to and transport oxygen throughout the circulatory system2.  
Hemoglobinopathies, genetic mutations affecting the hemoglobin, either decrease α or β 
globin production, or generate mutated, functional variants of the β-globin chains1.  Alpha 
globin is encoded by 2 genes located on the 16th chromosome: hemoglobin, alpha 1 (HBA1), 
and hemoglobin, alpha 2 (HBA2); however HBA2 produces 2-3 fold more protein than 
HBA13.  Beta globin is encoded by a single gene (hemoglobin, beta) located on the 11th 
chromosome.  The majority of hemoglobinopathies affecting African Americans arise from 
mutations to the hemoglobin, beta (HBB) gene1.  
 
Figure 1:  The human beta globin gene like cluster.   
LCR = Locus Control Region; HBE1 = Hemoglobin Epsilon;  
HBG2 = Hemoglobin Gamma G; HBG1 = Hemoglobin Gamma A;  
HBBP1 = Hemoglobin Beta Pseudogene 1; 
HBD = Hemoglobin Delta; HBB = Hemoglobin Beta 
 
The HBB gene-like cluster (Figure 1) extends over 80,000 bases, and includes 6 genes: 
hemoglobin, beta (HBB); hemoglobin, delta (HBD); hemoglobin, beta pseudogene 1 
(HBBP1); hemoglobin, gamma A (HBG1); hemoglobin, gamma G (HBG2); and hemoglobin, 
epsilon 1 (HBE1), which are regulated by a locus control region (LCR)4.  Each gene is 
structurally similar, arising from gene duplications during the early evolution of 
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invertebrates5.  With the exception of the pseudogene HBBP1, each gene produces functional 
globin proteins4.  As the names imply, HBB, HBD, HBG1, HBG2, and HBE1, produce beta 
globin, delta globin, gamma globin, gamma globin, and epsilon globin; respectively6.  The 
sickle mutation is an adenine to thiamine substitution occurring in the 6th codon of the human 
beta globin gene (HBB)7.  Transcription of the mutated DNA produces a functional variant of 
the β-globin protein, constructed with valine in the place of glutamic acid7.  Sickle β-globin 
combines with α-globin to form a protein product commonly referred to as hemoglobin S.  
While the hemoglobin of individuals with sickle cell anemia is almost entirely hemoglobin S, 
heterozygotes produce a combination of normal and mutated hemoglobin.  The concentration 
of hemoglobin S in SCT carriers varies considerably, ranging from 25-45%8.  In both SCT 
carriers and individuals with SCA, hemoglobin S production is known to be influenced by 
genetic modifiers, described subsequently in sections 2.5 and 2.8.  
2.3  Erythrocyte Sickling 
With deoxygenation, the erythrocyes of individuals with SCA become sickled and 
deformed1.  To a lesser extent, sickling is also observed in SCT carriers1.  Hemoglobin 
transports oxygen throughout the systemic arterial circulation2.  The oxygen is released in the 
microcirculation, and supplied to the tissues by diffusion through the capillary walls2.   When 
hemoglobin S releases oxygen, the aberrant valine within the mutated beta globin chains 
becomes exposed9.  Unlike glutamic acid, found in normal beta globin, valine is a nonpolar, 
hydrophobic amino acid9.  Valine fits within a hydrophobic pocket formed by glutamic acid 
and phenylalanine at the 88th and 85th residues, allowing it to bind to neighboring 
hemoglobin molecules9.  This activates a polymerization cascade, forming long chains of 
hemoglobin molecules that eventually stretch and distort the erythrocytes into a characteristic 
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sickle cell shape9.  At rest, approximately 30-60% of the erythrocytes in the deoxygenated 
venous circulation are sickled in individuals with sickle cell disease, compared to 1% in SCT 
carriers10.  However, under experimental conditions, the percentage of sickled red blood cells 
in SCT carriers has been shown to increase from 1.0 ± 1.0% at rest, to 8.5 ± 7.1%, with 
exercise at a simulated altitude of 4000 meters11.  Even under controlled conditions, a wide 
range of sickling (1% – 25%) among SCT carriers is observed11.   In addition to oxygen 
saturation, in vitro sickling is also influenced by temperature, pH, and the intracellular 
concentration of hemoglobin S12-14.  After several deoxygenation cycles, erythrocytes of 
individuals with SCA eventually become permanently sickled1.  However, sickling in SCT 
carriers is generally reversible, as red blood cells regain normal morphololgy with 
oxygenation in the arterial circulation1.  Irreversible sickling, evidenced by sickled red blood 
cells in the arterial circulation, is observed under experimental conditions in less than 1% of 
red blood cells in SCT carriers subjected to exercise testing11. 
2.4 Prevalence of Sickle Cell Trait 
 The sickled deformation of red blood cells is known to deter cytoadherance of 
Plasmodium falciparum, the parasite responsible for malaria15.  As a result, individuals 
producing hemoglobin S have fewer episodes of malaria or high-density parasitemia, defined 
as an excess of 10,000 parasites per μL of blood16.  While sickle cell anemia is a debilitating 
disease with an average life span of 44 years in the United States17, the sickle mutation 
confers a selective survival benefit to heterozygotes in areas with endemic malaria, even with 
adequate access to antimalarial treatments.  This is evidenced by a longitudinal study 
following 1022 children from a Kenyan birth cohort, which reported a decreased risk of all-
cause mortality in children with SCT, during the critical period between 2 and 16 months, 
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when clinical immunity to malaria has not yet developed.  Of note, all study participants with 
a detected fever and positive blood film were treated with sulfadoxine-pyrimethamine, an 
antimalarial drug16.  Due to selective pressure, the sickle mutation, though deleterious in its 
homozygous form, has a higher prevalence in the gene pools of populations arising from 
tropical regions.  In 2010, the world birth prevalence of SCT was estimated to be 5,476,000 
(IQR: 5,291,000 – 5,679,000) 18.  In support of the historic and possibly ongoing selective 
advantage of SCT in areas with endemic malaria, high allelic frequencies (>10%) of the 
sickle mutation were almost exclusively located in sub-Saharan Africa18.  In the United 
States, Americans with African ancestry have a much greater prevalence of SCT (8%) than 
those with European ancestry (0.3%)19.     
2.5 Sickle Haplotypes  
Haplotype blocks, long stretches of alleles linked to one another on a single chromosome, are 
often used to trace genetic ancestry.  While the DNA of unrelated individuals will differ at 
every 1000-2000 base pairs, identical polymorphisms within a haplotype block imply 
common ancestry20.  Five distinct haplotypes of the sickle mutation, Cameroon, Benin, Bantu 
(Central African), Senegal, and Arab, have been discovered, indicating the sickle mutation 
arose multiple times over the course of human history20.  The sickle haplotypes are named for 
their regions of discovery and geographical distribution.  Sickle haplotypes are detected by 
the presence or absence of restriction fragment length polymorphisms (RFLPs) around the 
beta globin gene cluster20.  When present, RFLPs are cleaved by the endonucleases Xmn I, 
Hind III, Hinc II, and Hpa I21.  While the Benin haplotype extends for 130 kilobase pairs, the 
Senegal and Bantu haplotypes extend for 76 kilobase pairs21.  In the United States, the most 
common sickle haplotypes are Benin, Bantu, and Senegal22.  Benin haplotypes are by far the 
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most prevalent, found in 61% of African Americans with SCA.23  By comparison the Bantu 
haplotype is found in 21%, and the Senegal haplotype in 10%23.  These haplotypes are 
associated with varying expression of the sickle mutation and hemoglobin S production, with 
Bantu being the most severe, and Senegal the mildest21.  Variability in severity is related to 
hemoglobin F production, described below.  
2.5a Fetal Hemoglobin and Sickle Haplotypes 
 Fetal hemoglobin, or hemoglobin F, suppresses the production and polymerization of 
hemoglobin S, mitigating the sickle phenotype1.  Hemoglobin F has a greater oxygen affinity 
than adult hemoglobin, and is structurally distinct, composed of 2 alpha globin chains and 2 
gamma globin chains (in the place of beta globin)1.  At birth, the concentration of 
hemoglobin F is 55-85%, which normally decreases to less than 1% in adults1.  However, 
multiple mutations, both within the HBB gene-like cluster and external to it, influence 
hemoglobin F production24.  Gamma globin is encoded by HBG2 and HBG1, both located on 
chromosome 11, within the HBB gene like cluster24.  Unlike the Bantu and Benin haplotypes, 
the Senegal haplotype block contains a SNP (rs7482144), located 158 base pairs upstream 
from HBG2, which is cleaved by endonuclease Xmn1 24.  This polymorphism is thought to 
be in linkage disequilibrium with functional elements increasing HBG2 expression; however 
the exact mechanisms of genetic modification are unknown24.  There is considerable 
variability in hemoglobin F and hemoglobin S production among the sickle haplotypes24.  
The Bantu haplotype is considered the most severe, with hemoglobin S comprising 90% of 
the total hemoglobin in individuals with SCA21.  The Benin haplotype is intermediate to the 
Bantu and Senegal haplotypes, with hemoglobin S making up 85% of the total hemoglobin in 
individuals with SCA, and hemoglobin F 10%.21  The Senegal haplotype results in the 
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mildest phenotype of SCA, with hemoglobin S comprising 75% of the total hemoglobin, and 
hemoglobin F concentrations approaching 20%21.  However, hemoglobin F is not influenced 
solely by sickle haplotypes.  Quantitative trait loci within the HBS1L-MYB intergenic region 
(rs9399137), and B-cell lymphoma gene (BCL11A, rs766432), also influence gamma globin 
production, explaining 30-50% of the variation in hemoglobin F concentrations among 
individuals with SCA24.  The impact of sickle haplotypes and fetal hemoglobin expression in 
SCT carriers has not been widely published in the literature. 
2.6 Sickle Mutation and Hypercoagulability 
 Both SCA and SCT are associated with increased factors of coagulation, when 
compared to African Americans with normal hemoglobin25.  This is likely due to red blood 
cell asymmetry and disordered cell membranes expressing phosphatidylserine25, 26.  Under 
hypoxic conditions, such as heavy exertion, dehydration, or high altitudes, the hemoglobin S 
of SCT carriers polymerizes, causing erythrocytes to sickle11, 27, 28.  As the red blood cells 
sickle, phosphatidylserine, a cellular recognition signal, is pulled from the interior of the 
phospholipid monolayer to the outside of the cell membrane surface29.  Phosphatidylserine 
serves as a docking site for enzymes which facilitate prothrombin activation, coagulation and 
clot formation30.  While red cell sickling is far less prevalent in SCT carriers than with SCA, 
evidence for hypercoagulability in SCT carriers has been indicated by blood assays26.  
Compared to African Americans with normal hemogloblin, SCT carriers have elevated levels 
of prothrombin fragment 1+2, thrombin-antithrombin complexes, and d-dimer26.  These 
biomarkers signify coagulation activation.  Prothrombin fragment 1+2 is a byproduct 
released by the conversion of prothrombin to thrombin, an integral step in the coagulation 
cascade.  D-dimer is a metabolite of fibrinolysis, indicating degradation of fibrin clots, and 
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an indirect biomarker of hypercoagulability26.  To some extent, the hypercoagulability in 
SCT carriers may be modified by environment or behavior.  This is evidenced by differing 
levels of procoagulant activity in monozygotic twins with SCT31. 
 Hypercoagulability increases risk of thrombosis, and a greater prevalence of 
thrombotic infarctions has been observed in individuals with SCT32-34.  In an autopsy series 
of 128 SCT carriers with a mean age of 47, obvious visceral infarcts were observed in 18%, 
after excluding cases with cardiac thrombi, bacterial endocarditis, and atherosclerotic 
emboli32.  By comparison, visceral infarcts were observed in less than 1% of similarly aged 
African Americans with normal hemoglobin.  The spleen was the most common site of 
infarction in SCT cases, followed by the kidneys, brain, and lung32.  A higher prevalence of 
thrombotic events has also been observed in SCT carriers in epidemiological studies.  In an 
observational study, 65,154 consecutively admitted African American males in 13 Veterans 
Administration hospitals were tested for SCT33.  Pulmonary embolism was noted in 2.2% of 
SCT carriers, compared to 1.5% with normal hemoglobin33.  Furthermore, in a case control 
study of 1070 hospitalized African Americans, SCT carriers were observed to have twice the 
risk of venous thromboembolism34.  Certain exposures may influence the risk of thrombosis 
in SCT carriers.  For example, oral contraceptive use has been associated with deep vein 
thrombosis in female SCT carriers of child bearing age35.    
2.7  Sickle Mutation and Vasculopathy 
 Vasculopathy, a general term denoting disorders of the vasculature, has been 
described in individuals with both SCA and SCT.  The arterial vasculature is regulated by the 
endothelial cells, which make up the tunica intima, or endothelium, lining the inner layer of 
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the arterial wall2.  When injured or stimulated by irritants, the endothelium becomes 
activated, releasing cellular signaling molecules that regulate vasomotor tone, inflammatory 
responses, coagulation, and vascular remodeling36.  Vascular remodeling may be either 
dilatative, as is the case with dolichoectasia, or occlusive, the result of hyperplasia, or 
thickening, or the intimal layer of the arterial wall.  Endothelial dysfunction and vascular 
remodeling associated with the sickle mutation will be described in greater detail next. 
2.7a  Sickle Mutation and Endothelial Dysfunction 
 Endothelial dysfunction is detectable by biomarkers and noninvasive testing37, and 
has been observed in both individuals with SCA and SCT38.   Hemolysis, bursting red blood 
cells, creates endothelial dysfunction by depleting the bioavailability of nitric oxide, a potent 
vasodilator produced by the endothelium, with anti-athrogenic and anti-thrombotic effects39.  
Sickled red blood cells are particularly friable, and when ruptured, release free hemoglobin 
and arginase into the blood plasma39.  Free hemoglobin binds to and scavenges nitric oxide, 
reducing its bioavailabiliy, while arginase converts L-arginine, a substrate required for nitric 
oxide production, into ornithine, decreasing nitric oxide formation39.  Among its many other 
effects, nitric oxide represses the expression of vascular cell adhesion molecules on the 
surface of endothelial cells40.  Accordingly, elevated cellular adhesion molecules can be 
considered biomarkers of endothelial dysfunction.  In laboratory assays, patients with SCA 
show elevated levels of soluble vascular cell adhesion molecules (sVCAM) compared to 
African Americans with normal hemoglobin, an indication of endothelial dysfunction39.   
In contrast to homozygous SCA, the erythrocytes of SCT carriers are less prone to 
rupture41.  However, after a single sickling episode provoked by hypoxia, SCT erythrocytes 
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have demonstrated hemolysis in vitro.41  While biomarkers of endothelial dysfunction have 
not been examined in SCT carriers, endothelial dysfunction in SCT carriers has been 
suggested by noninvasive tests.  One such test, flow mediated dilation (FMD) testing, 
measures the brachial artery response to induced hyperemia.  Briefly, the forearm blood flow 
is occluded by a tourniquet, and reactive hyperemia, or turbulent, high velocity blood flow, is 
induced upon release of the tourniquet.  The sudden increase in arterial wall sheer stress, 
caused by the hyperemic blood flow, stimulates the endothelium to release nitric oxide.  
Endothelial function is gauged by the degree of arterial dilation, measured by high resolution 
ultrasonography.  FMD testing has demonstrated endothelial dysfunction in SCA patients, 
and a dilation response in SCT carriers that is intermediate to SCA patients and African 
American controls with normal hemoglobin38. 
2.7b  Sickle Mutation and Intimal Hyperplasia 
Endothelial dysfunction and overexpression of vascular adhesion molecules induce intimal 
thickening, or hyperplasia in individuals with sickle hemoglobinopathies.  When expressed, 
the cellular adhesion molecules on the endothelial cell surface recruit white blood cells, and 
initiate their uptake into the vascular wall42.  Leukocytes secrete cytokines and growth 
factors, which induce smooth muscle cells to proliferate and migrate from the tunica media to 
the intima43.  The resulting vascular intimal hyperplasia can become stenotic, blocking the 
passage of blood by protruding into the arterial lumen42.  Additionally, the irregular surfaces 
of intimal lesions facilitate thrombus formation, as activated platelets adhere to sites of 
vascular injury44.  Arterial intimal hyperplasia with superimposed thrombi have been noted in 
deceased SCA patients, by post-mortem examinations.  An autopsy series 12 SCA patients 
with fatal stroke at a mean age of 21 reported arterial stenosis and intimal hyperplasia in 7, 
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and stenosis with occlusive thrombus in 645.  Few post-mortem examinations of vasculopathy 
in individuals with SCT have been published.  However, in one report of 20 consecutive 
patients who died of various causes (15 with SCA autopsied at mean age of 39, and 5 with 
SCT autopsied at a mean age of 51), intimal hyperplasia and fibrosis was observed in the 
pulmonary artery of all 2046.  Thus, intimal hyperplasia may be a common finding with SCT, 
at least in the pulmonary artery. Unfortunately, no comparisons can be made with African 
Americans with normal hemoglobin, as none were autopsied in this case series. 
2.7c  Sickle Mutation and Dolichoectasia 
Another form of vasculopathy, dilatative arteriopathy, has been detected by cerebral MRI in 
both patients with SCA and SCT.  Dolichoectasia, or dilatative arteriopathy, is characterized 
by elongated cerebral vessels following a tortuous, or sinuous course, with marked thinning 
of the arterial walls and dilation47.  Bidirectional blood flow within ectatic, or dilated, 
segments, results in blood stasis and intraluminal thrombus formation, which can lead to 
downstream infarctions in the cerebral circulation47.  In older individuals, dolichoectasia is 
most commonly associated with hypertension and atherosclerosis47; however, wall shear 
stress, induced by acute increases in blood volume and turbulent flow, has precipitated 
dolichoectasia in experimental animals48.  Chronic and uneven wall shear stress is thought to 
denude the endothelium, and degrade the internal elastic lamina of the arterial wall by 
stimulating the release of metalloproteinases49.  Sickle cell anemia is characterized by high 
cardiac output, as the heart compensates for anemia and oxygen demand by pumping a 
greater blood volume1, which may be related to the increased prevalence of dolichoectasia 
observed with SCA.  In a retrospective study of 47 children with SCA who were imaged by 
magnetic resonance angiography, 37% demonstrated ectasia of the basilar artery, compared 
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to 2% of controls without SCA, who were imaged to assess brain tumor50.  While 
heterozygous SCT is not characterized by anemia or high output states1, a prospective 
imaging study comparing SCT children to normal hemoglobin siblings reported a 
dolichoectasia prevalence of 19% in those with SCT, compared to none of the controls51.  
Thus, both the homozygous and heterozygous sickle mutation may be associated with 
dolichoectasia; however the mechanisms causing dolichoectasia in SCT carriers have not 
been elucidated. 
2.8  Sickle Cell Trait and Other Hemoglobinopathies 
 Several hemoglobinopathies, or mutations affecting alpha or beta globin production, 
are observed in populations of African descent.  These include alpha thalassemia, beta 
thalassemia, and Hemoglobin C (Table 1).  The SCT expression is influenced by co-inherited 
hemoglobinopathies.  While alpha thalassemia mitigates the phenotype, concomitant 
heterozygosity for SCT and beta thalassemia or SCT and hemoglobin C produces a disease 
state phenotypically similar to sickle cell anemia, exacerbating the impact of the SCT 
variant1.  The hemoglobinopathies affecting African Americans and their coinheritance with 
SCT are described in greater detail next.   
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Table 1:  Hemoglobinopathies and their prevalence in African Americans1, 19, 52, 53 
Hemoglobinopathy Gene(s) Mutations Presentation Prevalence 
Alpha Thalassemia  
(-- α / α α ) or 
(--α / -- α) 
HBA2 
Chromosome 16 
Δ3.7 kb deletion 
(heterozygous or  
homozygous) 
Asymptomatic to 
mild microcytic 
anemia 
30% 
 
Beta Thalassemia 
 
HBB 
Chromosome 11 
-88 (C-T) or 
-29 (A-G) 
Asymptomatic 
(heterozygotes) to 
severe anemia 
(homozygotes) 
1% 
 
 
Sickle Cell Trait 
 
HBB 
Chromosome 11 
Glu6Val  
(heterozygous) 
Carrier state 8% 
 
Sickle Cell Anemia HBB 
Chromosome 11 
Glu6Val  
(homozygous) 
 
Severe hemolytic 
anemia 
0.14% 
Hemoglobin C Trait HBB 
Chromosome 11 
Glu6Lys  
(heterozygous) 
Asymptomatic 2% 
Hemoglobin C 
Disease 
 
 
HBB 
Chromosome 11 
Glu6Lys  
(homozygous) 
Mild hemolytic 
anemia 
0.017% 
Hemoglobin SC 
Disease 
HBB 
Chromosome 11 
Glu6Val, Glu6Lys 
 
Severe hemolytic 
anemia 
0.08 - 0.12% 
 
Sickle β Thalassemia 
 
 
HBB 
Chromosome 11 
Glu6Val, β 
thalassemia 
Mild to severe 
hemolytic anemia, 
depending on  
β0 or β+ mutation 
0.02% -
0.05% 
Sickle Cell Trait  
Alpha Thalassemia  
 
HBB, HBA2 
 
 
Glu6Val and Δ3.7 
deletion 
Attenuated 
expression of sickle 
cell trait 
2.4% 
Sickle Cell Anemia  
Alpha Thalassemia  
 
HBB, HBA2 Homozygous 
Glu6Val and Δ3.7 
deletion 
Milder form of sickle 
cell anemia 
0.042% 
 
(-- α / α α ) = 3 functioning alpha globin genes, (-- α / -- α ) = 2 functioning alpha globin genes 
Glu6Val = glutamic acid to valine mutation, Glu6Lys = glutamic acid to lysine mutation 
β0 = no beta globin production, β+ = diminished beta globin production 
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2.8a Alpha Thalassemia 
Alpha thalassemias result from deletions to the alpha globin encoding genes (HBA2 
or HBA1), or mutations affecting their expression.  The alpha globin gene cluster spans 30 
Kb, and contains 5 genes:  hemoblobin, zeta (HBZ); hemoglobin zeta pseudogene 1 
(HBZP1); hemoglobin, mu (HBM, also referred to as hemoglobin alpha pseudogene 2, or 
HBAP2); hemoglobin alpha pseudogene 1 (HBAP1); hemoglobin alpha 2 (HBA2); 
hemoglobin alpha 1 (HBA1); and hemoglobin theta 1 (HPQ1), as shown in Figure 7.   
Over 120 mutations are associated with alpha thalassemia; however, the Δ3.7 deletion 
(rs63751476) of the HBA2 gene is most common in African Americans.  African Americans 
have a high prevalence (30%) of alpha thalassemia, defined by either a single (-- α / α α ) or 
double (-- α / -- α ) alpha globin gene deletion, denoting either heterozygosity or 
homozygosity for the Δ3.7 mutation52.  The clinical presentation of alpha thalassemia trait 
ranges from asymptomatic to mild microcytic anemia, characterized by small red blood 
cells1.  The more severe forms of alpha thalassemia, Hemoglobin H (--  -- / -- α )  and Barts 
Hydrops Fetalis (--  -- / -- --) are exceedingly rare in African Americans, and as a result the 
prevalence has not been estimated52.   
When coinherited with SCT, alpha thalassemia decreases hemoglobin S production1.  
Because alpha thalassemia minimizes the available pool of alpha globin chains, normal and 
Figure 2:  The alpha globin gene cluster contains 6 loci 
HBZ = Hemoglobin Zeta; HBZP1 = Hemoglobin Zeta Pseudogene 1; HBM = Hemoglobin Mu; 
HBAP1 = Hemoglobin Alpha Pseudogene 1; HBA2 = Hemoglobin Alpha 2;  
HBA1 = Hemoglobin Alpha 1; HBQ1 = Hemoglobin Theta 
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sickle beta globin must compete for available alpha chains to form hemoglobin tetramers1.  
Normal beta globin dimerizes twice as effectively as sickle beta globin, leaving sickle beta 
globin without available alpha chains to form hemoglobin S1.  In fact, hemoglobin S 
concentrations in SCT carriers depend on the number of functioning alpha globin genes.  
SCT carriers with all 4 alpha globin genes have hemoglobin S concentrations of about 40%, 
compared to 35% in SCT carriers with 3 functioning alpha globin genes, and 30% in those 
with 2 alpha globin genes52.   
The prevalence of alpha thalassemia in patients with SCA appears to be comparable 
to the general population of African Americans52, 54, 55.  Alpha thalassemia has been 
estimated to have a prevalence of 30% in African Americans52.  Similarly, a 1 or 2 alpha 
gene deletion was detected in 33% of SCA patients enrolled in the Cooperative Study of 
Sickle Cell Disease54, but was slightly higher (40%) in infants with SCA enrolled in the Baby 
Hug trial55.  Alpha thalassemia is inherited independently of sickle haplotype groups as 
well21.  Assuming a random coinheritance of alpha thalassemia with respect to sickle 
mutations or haplogroups, the expected prevalence of SCT and alpha thalassemia would be 
the product of each muation’s prevalence in African Americans, or 2.4%.                                                                          
2.8b Beta Thalassemia 
Beta thalassemias are hemoglobinopathies that diminish (β+) or abrogate (β0) 
production of the beta globin chains.  When coinherited with SCT, beta thalassemia increases 
the concentration of hemoglobin S.  This is because beta thalassemia decreases the number of 
normal beta globin chains, leaving a predominance of sickle beta globin chains1.  Sickle beta 
thalassemia, the coinheritance of SCT and β+ thalassemia, results in mild hemolytic anemia1.  
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On the other hand, SCT that is coinherited with β0 thalassemia has a clinical presentation that 
is almost indistinguishable from sickle cell anemia1.  Over 200 mutations are known to cause 
beta thalassemia.  In African Americans, the -88 (CT) and -29 (AG) mutations, affecting 
promoter regulatory elements of the HBB gene, are the most frequent cause of beta 
thalassemia56.  In African American birth cohorts, the prevalence of beta thalassemia is 1%53, 
while the prevalence of coinherited SCT and beta thalassemia is 0.02 – 0.05%19, 53.   
2.8c Hemoglobin C 
 Similar to hemoglobin S, hemoglobin C is a functional variant of the beta globin gene 
(rs33930165), caused by a single nucleotide polymorphism of the 6th codon of the 
hemoglobin gene1 (Figure 8).  While sickle beta globin contains a glutamic acid to valine 
substitution, hemoglobin C produces a mutated beta globin protein with lysine in the place of 
glutamic acid1.  The heterozygous genotype, or hemoglobin C trait, is asymptomatic.  The 
homozygous genotype, known as hemoglobin C disease, is characterized by mild hemolytic 
anemia.  In African Americans, the prevalence of hemoglobin C trait is 2%, while the 
prevalence of hemoglobin C disease is much rarer, at 0.017%19. Concomitant heterozygosity 
of SCT and hemoglobin C, however, results in hemoglobin SC disease, a hemolytic anemia 
with symptoms of vaso-occlusive crises and acute chest syndrome57.  In African American 
birth cohorts, the reported prevalence of hemoglobin SC disease in ranges from 0.008 – 
0.12%19. 
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Figure 3:  Single nucleotide polymorphisms on 6th codon of beta globin gene 
2.9 Summary of Primary Exposure: SCT 
 Sickle cell trait, the heterozygous form of sickle cell anemia, affects approximately 
8% of African Americans.  Laboratory assays and observational studies suggest greater risk 
of adverse vascular events associated with SCT.  Under hypoxic conditions, the hemoglobin 
S polymerizes, increasing hypercoagulability and risk of venous thromboembolism in SCT 
carriers.  The sickle mutation is also associated with vasculopathies, and a greater degree of 
endothelial dysfunction, intimal hyperplasia, and dolichoectasia.  However, the sickle 
mutation is affected by several genetic factors.  Hemoglobin F production, influenced by 
polymorphisms within the sickle haplotype blocks, and coinheritance of alpha thalassemia, 
reduce the production of hemoglobin S, mitigating the severity of the SCT phenotype.  On 
the other hand, a concomitant heterozygosity of SCT and Hemoglobin C, or the coinheritance 
of SCT with β0 thalassemia, results in a phenotype that more closely resembles sickle cell 
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anemia.  Thus, the hypothesized associations between SCT and cerebrovascular disease may 
be influenced by concomitant hemoglobinopathies and haplotype. 
3. STROKE  
3.1 Overview 
 Stroke, or cerebrovascular accident, is an acute neurologic syndrome provoked by 
interrupted blood supply to the brain58.  The cerebral neurons lack glycogen; as a result, 
blood flow cessation precipitates rapid energy failure followed by brain tissue death within 4 
– 10 minutes58.  Blood flow disturbances originate from vascular obstructions and ruptured 
blood vessels, and occur in both the large and small cerebral vessels58.  The large intracranial 
arteries include the internal carotid arteries, vertebral arteries, and the middle, anterior, and 
posterior cerebral arteries, which make up the Circle of Willis.  The small vessels, which 
typically range from 400 – 900 μ in diameter, branch from the large vessels deep into the 
interior of the brain58.  While most cerebral vascular accidents involve the large vessels, the 
small vessels are implicated in 20%58.  Stroke more often involves the arterial circulation; 
however, cerebral vascular accident is also provoked by disrupted blood flow in the cerebral 
veins and sinuses58.  
3.2 Ischemic Stroke 
 The majority of strokes are ischemic, accounting for 87% of all cerebrovascular 
accidents59.   Ischemic strokes are caused by vascular obstructions from clot or atheroma, 
with origins that are more often embolic than in-situ58.  Common sources of emboli include 
the heart and proximal extracranial arteries, and to a lesser extent, the venous circulation58.  
Cardioembolic stroke, provoked by embolized blood clots originating in the heart, account 
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for 20% of all ischemic strokes58.  Clotting is induced by stasis of the left atrium, due to low 
ejection fraction, atrial fibrillation, and left atrial dilation.  Another source of embolic stroke 
is the extracranial carotid arteries58.  The bifurcation of the internal carotid is particularly 
vulnerable to atherogenesis.  Thrombus forming on the plaque surface can dislocate, or the 
plaque itself can rupture and break loose, forming emboli that eventually become lodged in 
the intracranial vessels.  A third source of emboli is the venous circulation, causing ischemic 
stroke by so-called paradoxical embolization58.  Under normal circumstances, blood from the 
systemic venous circulation is returned to the right atrium, and ejected by the right ventricle 
to the lungs.  However, in 15% of the general population, blood communicates from the right 
to left atrium, through a small opening in the atrial wall, or atrial septal defect58.  This 
passage allows embolized clot from the venous circulation, often from deep vein thrombosis, 
to cross the cardiac circulation and become ejected into the systemic arterial circulation.  
Compared to embolic stroke, vascular obstruction by in-situ thrombosis is less frequently 
observed, and usually occurs in either the small deep penetrating arteries, or the cerebral 
veins and sinuses58.  Stenotic plaques, typically in the carotid or vertebral arteries58, also 
provoke ischemic stroke by inducing hypoperfusion to the downstream cerebral circulation.  
In the United States, the 30-day case fatality rate of ischemic stroke is 7.8%60 
3.3 Hemorrhagic Stroke 
 Cerebrovascular accidents that arise from ruptured blood vessels, rather than vascular 
obstructions, are termed hemorrhagic strokes.  Hemorrhagic strokes are particularly deadly, 
with a case fatality rate of 50%58.  The most common type of hemorrhagic stroke is 
hypertensive intraparenchymal hemorrhage, invoked by spontaneous rupture of the small, 
deep penetrating arteries58.  Following arterial rupture, blood seeps into the ventricular spaces 
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of the brain, causing hydrocephalus and increasing intracranial pressure perniciously58.  
Hemorrhagic stroke is sometimes characterized by bleeding into the subarachnoid space 
between the brain tissue and the pia mater membrane surrounding the brain58.  Subarachnoid 
hemorrhage may result from ruptured aneuryms, weakened areas of the arterial wall, and 
generally arise from the large vessels comprising the Circle of Willis58.  Other causes of 
subarachnoid hemorrhage include trauma, and congenital arteriovenous malformations58.  
Arteriovenous malformations allow abnormal communication between the arteries and veins, 
bypassing the capillary circulation, and are prone to rupture58.   
3.4 Stroke Symptoms 
Symptoms and severity of stroke depend on type of obstruction, size of vessel 
impacted, extent of collateralization, and brain region supplied by the arterial distribution58.  
Symptoms are almost always contralateral to the brain hemisphere affected, with functional 
disability reflecting the brain region impacted58.  Limb paralysis (hemiplegia), limb weakness 
(hemiparesis), impaired gait (ataxia), and clumsy hand suggest damage to the sensory and 
motor cortex58.  Aphasia (language deficit) implies damage to Broca’s or Wernicke’s area of 
the cerebral cortex, while homonymous hemianopia (visual field loss) indicates injury to the 
cerebral visual cortex58.  The stroke syndrome may also present with severe memory loss, 
stupor, coma, loss of consciousness, and seizure58.   
Infarction of the small, deep penetrating arteries, or lacunar stroke, is typically less 
severe than stroke related to the large vessels.  In fact, small vessel infarcts are almost always 
ruled out by presentation of severe memory loss, stupor, coma, aphasia, monoplegia, 
homonymous hemianopia, loss of consciousness, or seizures61.  The vascular distributions of 
 21 
 
the small vessels are less extensive than the large vessels, minimizing areas affected by 
infarction.  Lacunar infarcts are also more often due to thrombi, which occasionally lyse, 
restoring the passage of blood flow58.  Episodes of stroke symptoms lasting less than 24 
hours, considered transient ischemic attacks (TIA), are often provoked by blood clots of the 
small vessels that quickly lyse, allowing functional recovery58.  However, TIAs are not 
without risk; in 10-15% of TIA cases, major stroke occurs within 3 months58.          
3.5 Stroke Diagnosis 
 Acute stroke is suspected by abrupt changes in mental status with presentation of 
neurological symptoms, and diagnosed by imaging studies and assessment of cerebral spinal 
fluid by lumbar puncture58.  Hemorrhagic stroke is distinguished from ischemic stroke by the 
presence of blood in the cerebral spinal fluid, and hemorrhaging in the absence of infarction.  
Computed tomography (CT) is generally preferred for acute stroke diagnosis, due to its speed 
and lower cost than magnetic resonance imaging (MRI)58.  CT imaging reliably detects 
intracranial hemorrhaging, but may not visualize infarctions until 24-48 hours after the 
event58.  Small infarctions along the cortical surface of the brain or within the posterior fossa 
may also be missed, due to bone artifact obstructing the image58.  As an alternative to CT, 
cerebrovascular accident may be diagnosed with MRI.  While MRI has less sensitivity 
visualizing hemorrhagic bleeding, it is a superior imaging modality for the detection of 
infarctions in all regions of the brain58.  One limitation to stroke diagnosis, either by CT or by 
MRI, is the patient’s ability to seek medical care.  Stroke symptoms are frequently painless, 
or cause anosagnosia, the lack of perception that anything is wrong58.  As a result, patients 
who live alone may not have the foresight to call emergency medical services for help.   
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3.5a.  Stroke Diagnosis in Epidemiological Studies 
 In large observational studies, stroke cases are often classified by administrative 
claims records, hospital surveillance, chart reviews, or diagnostic algorithms.  The 9th 
International Classification of Disease (ICD-9) codes, submitted to insurance carriers for 
billing purposes, provide a facile but imperfect record of patients discharged with stroke.  To 
ascertain stroke diagnoses, epidemiological studies sometimes examine abstracted medical 
records, including the physician notes and diagnostic imaging reports60.  One disadvantage of 
retrospective data collection after hospital discharge is the possibility of missing data relevant 
to the study aims.  Unlike prospective study designs, which rigorously record clinical data 
related to pre-specified outcomes, retrospective surveillance, or “cold pursuit”, is limited to 
recorded data deemed relevant to the patients’ clinical care62.  For this reason, stroke 
diagnoses by chart reviews often include measures of uncertainty.  For example, stroke may 
be considered “definite” when classified by clinical symptoms, imaging studies, and lumbar 
puncture.  On the other hand, stroke may be classified as “probable” when the clinical picture 
suggests stroke, but the diagnosis does not meet certain criteria for the epidemiological 
definition, for example if imaging studies are inconclusive, or lumbar puncture is not 
performed60.  Agreement between ICD-9 diagnoses and chart reviews varies, based on the 
stroke subtype and the number of ICD-9 codes analyzed.  In a study of 206 patients 
hospitalized with stroke, ischemic stroke was more accurately classified by considering all 
ICD-9 codes in the discharge record, while intracerebral and subarachnoid hemorrhage were 
better classified by considering only the primary ICD-9 discharge code63.   Physician-
reviewer validation of ICD-9 codes has also been ascertained in the ARIC study, which 
reported greater agreement between ICD-9 codes and subarachnoid hemorrhage (86%), than 
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ICD-9 codes and ischemic stroke (78%)60.  In some epidemiological studies, reviewing the 
medical record may be too labor intensive or cost-prohibitive.  As an alternative, a validated 
computer algorithm may be utilized to diagnose stroke cases, based on neurological signs and 
symptoms64.  In the ARIC study, which examined 538 stroke hospitalizations, agreement 
between computer algorithm and physician reviewer diagnoses was 78%60. 
3.5b.  Cerebral Magnetic Resonance Imaging 
 Cerebral small vessel disease is often detected in clinical settings and observational, 
prospective screenings by magnetic resonance imaging.  MRI scanners use magnetic field 
sequences to manipulate hydrogen protons, and convert the signals from protons returning to 
baseline energy states into images.  Hydrogen atoms are present in 99.98% of all human 
tissues65.  Positive subatomic particles, or protons, continuously rotate within the nuclei of 
atoms, creating a magnetic field.  When atoms are subjected to an external magnetic field, the 
protons start to rotate around the axis of the magnetic field, in a direction that is either 
parallel or antiparallel to the field65.  This interaction creates magnetic resonance.  After the 
MRI scanner aligns atoms within a magnetic field, a second magnetic field, or excitation 
pulse, is applied, pulling the atoms to a specified angle that is transverse to the first magnetic 
field.  The excitation pulse is then switched off, and protons are monitored as they return to 
the original alignment65.  The return time is dependent on the tissue.  For example, the 
relaxation time for hydrogen protons in fat is very brief, while the relaxation time in fluids is 
very long65.  These return time signals are converted into voxels, or 3D pixels, by fast Fourier 
transform, allowing a visual representation of the tissues.  For image optimization, the 
magnetic resonance signal can be filtered, or weighted, by manipulating the repetition time 
and echo time of the excitation pulse65.  Two sequences, called T1 and T2 weights, may be 
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used, depending on the structures being visualized.  When both the T1 and T2 weights are 
removed, MRI is considered proton density weighted, meaning the magnetic resonance 
signals are proportional to the water concentration65.  Brain imaging is also optimized by 
fluid attenuated inversion recovery, or FLAIR, which filters signals arising from the cerebral 
spinal fluid65.      
3.5c.  Subclinical Stroke Detection by MRI 
 Silent stroke is unaccompanied by neurological symptoms, but is detectable by a 
presentation of white matter lesions or subclinical brain infarctions on MRI.66  Severity of 
white matter lesions is either quantified volumetrically, or graded qualitatively from 2-
dimensional images67.  Subclinical brain infarctions, which present on MRI as fluid-filled 
lacunes, are quantified by measuring the largest diameters68.  In highly selected populations, 
such as patients with Alzheimers69 or Binswangers disease70, MRI-detected WML and 
lacunes have been validated by autopsy.  However, silent stroke detected by MRI in the 
general population is not likely to be validated by autopsy, and few cohorts incorporate post-
mortem examination with prospective MRI.  Despite this limitation to validity, the detection 
of subclinical cerebrovascular disease by MRI is reproducible (discussed further in sections 
4.1 and 5.1).  Reliability is typically tested among randomly selected duplicate images, to 
determine intra- and inter-reader reproducibility67, 71, 72.  An advantage of MRI is its 
suitability for prospective imaging in observational studies58.  Unlike CT, which exposes a 
patient to 3-5 mGy of radiation for a routine brain exam, MRI does not utilize ionizing 
radiation58.  However, MRI is time consuming and sensitive to motion, and children under 
the age of 10 typically require conscious sedation to remain immobile for the duration of the 
test58.  In addition, metal objects must be removed prior to MRI examination65.  Study 
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participants with metallic implants, such as aneurysm clips, hearing aids, cardiac 
pacemakers, spinal cord stimulators or other internal electrical devices must be excluded.  
Other considerations include extreme obesity and claustrophobia.  As the MRI scanning 
involves bodily insertion into the magnet bore, patients unable to fit, or tolerate, confined 
spaces may need to be excluded.   
3.6 Stroke Prevalence 
In the United States, approximately 7 million people over the age of 20 have had a 
stroke59.  The Southeast has the greatest density of stroke cases, clustered within the so-called 
stroke belt:     Alabama, Arkansas, Georgia, Indiana, Kentucky, Louisiana, Mississippi, North 
Carolina, South Carolina, Tennessee, and Virginia73.  Stroke occurrence increases with age, 
and is more prevalent in women than men.  At the ARIC study baseline, the prevalence of 
TIA or stroke symptoms in women was 7%, compared to 5% in men (p<.0001)64. However, 
the greater prevalence of stroke in women appears to be predominantly due to the longer 
lifespans of women74.   African Americans are disproportionately burdened by 
cerebrovascular disease, and experience first stroke at a younger mean age than European 
Americans75.  The prevalence of stroke in African Americans18 years or older is nearly twice 
that of than non-Hispanic whites (4.0% vs. 2.3%)76.  Annually, the incidence of stroke in the 
United States has been estimated to be about 800,000 cases per year59, and has been 
decreasing since the 1990s for European Americans.  However, this trend has not been 
observed for African Americans77.  Over 8 years of follow up, a longitudinal analysis from 
the ARIC study reported a 62% higher stroke incidence rate in African Americans than 
European Americans (incidence rate ratio = 1.62; 95% CI: 1.22 – 2.14), after controlling for 
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age, gender, hypertension, diabetes, center, education, smoking, and history of coronary 
disease60.                                  
3.7 Stroke Risk Factors 
Risk factors for stroke vary by stroke type; however, hypertension is a strong 
determinant of both ischemic and hemorrhagic stroke58.  Additional risk factors associated 
with ischemic stroke include older age, diabetes, smoking, hyperlipidemia, atrial fibrillation, 
and recent myocardial infarction.  On the other hand, hemorrhagic stroke is correlated with 
aging, hypertension, trauma, congenital arteriovenous malformation, and amyloid 
angiopathy, the deposition of amyloid proteins within the brain and arterial walls58.   
Endothelial dysfunction and dolichoectasia may increase the risk of lacunar stroke.  
While endothelial heterogeneity is known to exist among the various vascular distributions36, 
there is evidence that systemic endothelial dysfunction correlates with cerebral small vessel 
disease and lacunar stroke.  In a cross sectional study of 45 Korean patients with 
symptomatic lacunar stroke undergoing flow mediated dilation testing, greater endothelial 
dysfunction of the brachial artery was noted in the stroke patients than the age and sex 
matched controls with hypertension78.  Lacunar stroke has also been cross sectionally 
associated with intracellular adhesion molecule (ICAM-1), tissue factor, and 
thrombomodulin, all biomarkers of endothelial dysfunction79.  Dolichoectasia appears to be a 
risk factor for lacunar stroke, as well.  In a population-based study of 387 patients with first 
cerebral infarction, 42% with dolichoectasia were diagnosed with lacunar infarct, compared 
to 17% without dolichoectasia80.   
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3.7a.  Genetic Risk Factors of Stroke 
 Family history and twin studies have predicted both ischemic and hemorrhagic stroke, 
implying a genetic component of stroke risk59.  Of the few studies that have reported 
genome-wide associations between SNPs and stroke, none have been conducted in 
populations of African ancestry.  However, in European populations, variants of the histone 
deacetylase (HDAC9) gene81, 82, paired-like homeodomain (PITX2) gene82, and Ninjurin 
(NINJ2) gene83 have been shown to have validated associations with large vessel stroke, at 
genome-wide statistical thresholds (p-value of 10-8 or smaller). 
3.8  Sickle Cell Anemia and Stroke 
 Sickle cell anemia is a well-established genetic risk factor for stroke.  The 
Cooperative Study of Sickle Cell Disease, a longitudinal cohort of 4,082 patients with sickle 
cell disease (sickle cell anemia, sickle hemoglobin C, and sickle thalassemia), observed that 
by the age of 45, 24% of patients with sickle cell anemia had experienced a first stroke, 
defined ischemic stroke, hemorrhagic stroke, or TIA84.  This association is confirmed by 
administrative claims data for stroke.  The incidence of ischemic stroke in patients with 
sickle cell anemia aged 35-64 is 740 per 100,000 person years85, much higher than 270 per 
100,000 person years for 35-64 year old African Americans overall86.  Unlike the general 
population, ischemic stroke in patients with SCA is often due to arterial narrowing with 
thrombus that is in-situ, rather than embolic.  In an autopsy series of children with SCA and 
fatal stroke, intimal hyperplasia with superimposed thrombosis were common findings, 
particularly in the middle and anterior cerebral arteries45.  In-situ thrombosis of the small 
cortical veins and the lateral and sagittal sinuses, the site of venous confluence within the 
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brain, are also observed with SCA58.  Stroke risk in children with SCA is determined 
noninvasively by transcranial Doppler, used to detect stenotic lesions and increased blood 
flow velocities within the Circle of Willis87.   
3.8a Genetic Modifiers of Sickle Cell Anemia and Stroke Risk 
 The stroke risk associated with sickle cell anemia is heterogenous, and may be 
influenced by coinheritance of modifier genes.  Support for this hypothesis comes from a 
pediatric sibship study, examining siblings who were all affected by sickle cell anemia88.  In 
42 of the 207 sibships, at least one child experienced clinical stroke, and in 10 sibships, 2 
siblings had a stroke.  The number of families with 2 children with SCA and stroke exceeded 
expectations derived by permutation analysis, leading the authors to conclude that 
coinheritance of genetic modifiers shared among siblings with SCA increased stroke risk88.  
The sickle haplogroups, alpha thalassemia, and candidate genes associated with stroke in the 
general population have been investigated as potential genetic modifiers of the association 
between sickle cell anemia and stroke, and are described next.      
3.8b Sickle Cell Anemia and Stroke Risk Modification by Haplotype 
 Stroke risk modification by haplogroup polymorphisms remains uncertain.  In a cross 
sectional study of 221 patients with sickle cell anemia, the Bantu haplotype, the most severe 
SCA phenotype with the greatest concentration of hemoglobin S, was associated with a 3-
fold increase in obliterative sickle vasculopathy, an outcome that included stroke, renal 
failure, chronic lung disease with cor pulmonale, leg ulcers, and young adult death21.  
However, a similarly sized case-control study that examined stroke as an explicit, rather than 
composite, outcome, found no differences in stroke prevalence among the 5 haplotype 
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groups89.  While statistical power calculations were not described, this study included 130 
children with SCA and stroke, and 103 SCA controls without stroke89.  Stroke risk 
modification by sickle haplogroups remains an interesting hypothesis, but at the current state 
of science, is far from established.                                                                        
3.8c Sickle Mutation and Stroke Risk Modification by Alpha Thalassemia 
Concomitant alpha thalassemia may also modify stroke risk in patients with SCA, and 
appears to protective effect21, 89, 90.  In a cross sectional study of 300 children with SCA, the 
prevalence of confirmed alpha thalassemia in children experiencing stroke (21%) was lower 
than those who were stroke free (38%)90.  These findings were later replicated by a pediatric 
case-control study including 233 children with SCA and alpha thalassemia detecting by 
genotyping89.  In SCT carriers, stroke risk modification has been investigated less 
extensively.  In a single study examining 355 hospitalized black men with SCT, no 
differences in stroke risk were observed among quartiles of hemoglobin S concentrations91.  
While alpha thalassemia was not ascertained by genotyping, it was inferred by hemoglobin S 
concentrations and mean corpuscular volume.  However, these biomarkers may be 
confounded by iron-deficiency anemia91, leaving the results inconclusive.    
3.8d Sickle Cell Anemia Stroke Risk Modification by Candidate Genes 
 Several candidate genes known to influence the development of vascular disease have 
been validated as stroke risk modifiers in children with sickle cell anemia.  In the 
Cooperative Study of Sickle Cell Disease (CSSCD), which included 1,398 African 
Americans with SCA, 108 SNPs in 80 candidate genes were analyzed by Bayesian networks 
for associations with stroke92.  From this analysis, 25 SNPs in the adenylate cyclase 
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(ADCY9), annexin (ANXA2), bone morphogenic protein (BMP6), chemokine ligand (CCL2), 
colony stimulating factor (CSF2), endothelin converting enzyme (ECE1), v-ets virus 
oncogene (ERG), met-proto oncogene (MET), selectin p (SELP), Tek tyrosine kinase (TEK), 
transforming bone growth factor beta receptor (TGFBR3) and tumor necrosis factor (TNF-α) 
genes were found to be associated with stroke92.  Genetic associations were then validated in 
114 African Americans with SCA not included in the original Bayesian analysis, and were 
found to predict stroke over a 5 year follow up with an accuracy of 98.2%92.   
Candidate genes have also been associated with large and small vessel stroke 
subtypes, classified by MRI.  In a validation study involving the CSSCD cohort and Stroke 
Prevention Trial in Sickle Cell Anemia (STOP), variants of tumor necrosis factor (TNF -308 
G/A) and interleukin 4 (IL4R 503 S/P) were found to protect against and increase the risk of 
large vessel disease, respectively93.   Genetic polymorphisms have also been associated with 
small vessel disease, in children with SCA prospectively screened by MRI.  In the CSSCD 
study, variants of the vascular cellular adhesion molecule (VCAM1 -1594) and the major 
histocompatibility complex, class II (HLA-DPB1) were associated with small vessel 
infarctions and silent stroke94; however, replication studies are needed to confirm these 
associations. 
3.9 Stroke Burden  
Stroke is a leading cause of both long-term disability and death in the United States, 
and African Americans shoulder the greatest burden.  Severe to moderate disability has been 
reported in 43% of elderly stroke survivors participating in the Framingham Study, which 
quantified activities of functional living using the Barthel scale95.  However, the Framingham 
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study did not include African Americans.  The National Health and Interview Survey, a more 
representative sample of 1,613 stroke survivors, revealed greater activity limitations in 
African Americans than European Americans, after adjusting for age, sex, and income.  
African Americans were more likely to report difficulty standing for more than 2 hours, 
pushing or pulling large objects, walking a quarter of a mile, stooping, bending, or kneeling, 
and walking up 10 steps without resting96.  While stroke is the fourth overall leading cause of 
death in the United States97, this too is disproportionately high for African Americans.  In 
2009, the age-adjusted stroke death rate per 100,000 was 62 for African American men, 
compared to 38 for non-Hispanic White men97.  Racial disparities were also noted for 
women; the adjusted death rate for African American women was 51, compared to 37 for 
their non-Hispanic White counterparts97.     
Stroke is not only twice as prevalent in African Americans compared to European 
Americans, it occurs at a younger age, resulting in substantial loss of potential earnings75.  
When direct and indirect costs are considered, including ambulance services, hospitalization, 
rehabilitation, outpatient clinics, prescription drugs, nursing homes, informal caregiving, and 
potential lost earnings, the projected cost of stroke from 2005-2050 is $1.52 trillion for non-
Hispanic whites, and $379 billion for African Americans75.  However, the per capita cost of 
stroke is projected to be $25,782 for African Americans, substantially higher than $15,597 
for European Americans75.    
3.10 Summary of Stroke 
 Stroke is a leading cause of disability and death in the United States, and African 
Americans are more often affected.  Stroke may be ischemic or hemorrhagic, and may arise 
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from the large vessels, small deep penetrating arteries, or veins and sinuses.  Stenotic 
atherosclerosis and embolized blood clots from the heart and venous circulation increase 
stroke risk, while in-situ thrombosis of the small vessels and vasculopathies contribute to 
lacunar stroke and TIA.  Sickle cell anemia is an established genetic risk factor for stroke, 
associated with intimal hyperplasia and narrowing of the large cerebral vessels, with 
superimposed in-situ thrombosis.  However, the stroke risk associated with SCA may be 
modified by haplotype group, concomitant alpha thalassemia, and candidate genes associated 
with vascular disease in the general population.  The associations between SCT and stroke, 
and modification by candidate genes, alpha thalassemia, and haplotypes are largely 
unexplored. 
4. SUBCLINICAL BRAIN INFARCTIONS 
4.1 Overview 
Lacunar infarcts, or blockages of the small, deep, penetrating arteries of the brain, are 
often considered subclinical brain infarctions (SBI) when asymptomatic.  Upon healing, 
subclinical brain infarctions leave behind small fluid-filled cavities, or lacunes, of necrosed 
cerebral tissue.  Lacunes typically measure 3 – 20 mm in diameter.  In epidemiological 
studies, SBI are detected by prospective MRI, using T1 and T2 weighted imaging in the gray 
matter, and T1 weighted imaging in the white matter.  While MRI-detected SBI are seldom 
validated by post-mortem examination, image reliability has been reported, with intra- and 
inter-reader reproducibility measures of 82% and 79%, respectively71. 
 
 
 33 
 
4.2 Etiology of Subclinical Brain Infarctions 
 The etiology of SBI appears to be heterogeneous, and related to vascular obstruction 
by atheroma, blood clots, and small artery stenosis98.  Brain autopsies identifying the source 
of lacunar infarctions are infrequently done, as this requires uninterrupted serial sections of 
the basal ganglia, tracing the infarcted area proximally until an occlusion is found98.    
However, from the few published autopsy reports, obstructions of the penetrating arteries 
appear to be due to embolic particles of atheroma, or to hyalinosis, an adaption to 
hypertension that results in hypertrophic growth of the arterial walls that eventually occludes 
the lumen61.  In lacunar infarcts with no obstructions identified by autopsy, thrombus has 
been implicated, as blood clots lyse and disappear within days of an embolic event98.  
Occlusion by thrombus is further supported by an association between subclinical brain 
infarctions and factors of coagulation (d-dimer and von Willebrand factor) in a cross 
sectional sample of older adults from the ARIC study99.   
4.3 Prevalence of Subclinical Brain Infarctions 
 The prevalence of SBI appears to increase with advanced age, and may be higher in 
African Americans than European Americans71, 100. During the baseline MRI exam of the 
ARIC study, 1890 participants aged 55-72 were prospectively imaged by brain MRI.  The 
overall prevalence of SBI was 15%, and increased with age from 8% in 55-59 year olds to 
23% in 65-72 year olds71.  The SBI prevalence was also shown to be higher in African 
Americans (21%), compared to European Americans (10%).  Similar trends were observed in 
the Cardiovascular Health Study, which prospectively imaged 3,658 participants aged 65 and 
older, using identical definitions for SBI as the ARIC study.  The SBI prevalence increased 
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from 22% in 65-69 year olds, to 43% for those over the age of 85 years100.  However, no 
differences in SBI prevalence was observed between African Americans and European 
Americans in the CHS study. 
4.4 Risk Factors of Subclinical Brain Infarctions 
 Risk factors for SBI have primarily been inferred from cross-sectional studies of the 
general population imaged by cerebral MRI.  Age and hypertension were the most 
consistently reported risk factors in a systematic review of 21 cross-sectional and 3 
longitudinal analyses of SBI66.  However, traditional risk factors for stroke, such as sex, 
cardiovascular disease, smoking, and diabetes have been reported as well66.  The risk factors 
for SBI may vary, due to heterogeneous etiologies of microatheroma, hyalinosis, and 
thrombosis.  A cross-sectional analysis from the ARIC study, which examined small (3–7 
mm) and large (8-20 mm) lacunes separately, found age, race, hypertension, smoking, and 
diabetes to predict small lacunes, while age, hypertension, smoking, and LDL cholesterol 
predicted large lacunes68.  The authors concluded that hyalinosis is predominantly 
responsible for the small SBI, and atheroma putatively causing the large lesions68.  However, 
lacunes measuring 5 – 20 mm have been detected by autopsies, with thrombus implicated as 
the cause98.  As with stroke, cardiac risk factors appear to be associated with SBI; however, 
the size of the lacunes may not always discriminate the etiology. 
4.5 Sickle Cell Anemia and Subclinical Brain Infarctions 
 Genetic risk factors may also predispose development of SBI.  The sickle mutation 
appears to be a genetic risk factor for lacunes, at least in homozygotes101.  In the CCSCD 
study, SBI was the most common neurological manifestation observed in children with 
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SCA101.  However, few studies have examined this outcome, due to the cost of magnetic 
resonance imaging, sedation requirement in small children, and lack of effective 
interventions101.  From the few studies that have been conducted, SBI appears to affect 27% 
of children with SCA under the age of 6, and 37% under the age of 14101.  While SBI is not 
accompanied by overt signs of clinical stroke, it is associated with poor academic 
achievement and future stroke in children with SCA101.  The prevalence of SBI in adults with 
SCA is not well established.  In a cross sectional study of 149 patients with a mean age of 32 
years, lacunes were detected in 13% of SCA patients, compared to 2% of age, sex, and 
education matched African American controls102.  However, this study used a more 
restrictive definition of SBI, requiring lesions to exceed 5 mm in diameter, and to be 
visualized by both T1 and T2 weighted MRI images101.  To date, no publications have 
examined heterozygous SCT as a genetic risk factor for subclinical brain infarctions. 
4.6 Burden Associated with Subclinical Brain Infarctions 
 Though asymptomatic, SBI are associated with subtle neurological deficits and future 
cognitive decline103.  In the Cardiovascular Health Study, baseline MRI exams were 
performed on 1433 participants, with follow-up MRI performed 5 years later.  Participants 
developing incident SBI scored worse on the Modified Mini-Mental State Examination and 
the Digit-Symbol Substitution test, both validated measures of cognitive performance103.  
These results are consistent with the Rotterdam Scan Study, which prospectively imaged 
1015 stroke-free, elderly participants by MRI.  Participants with SBI were found to have a 
steeper decline in cognitive function, and more than twice the risk of developing dementia or 
Alzheimer’s disease104.  Longitudinal studies have also reported an association between SBI 
and future stroke.  Over an average follow up of 4 years, the Cardiovascular Health Study 
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reported a hazard ratio for stroke of 1.5 (95% CI: 1.1 – 2.1) in participants with SBI, 
compared to those without105.  Stroke risk also appeared to be related to the number of 
infarctions; participants with multiple SBI were found to have twice the risk of subsequent 
stroke105. 
4.7 Summary of Subclinical Brain Infarctions 
 Infarctions of the small, deep penetrating arteries are often asymptomatic, but are 
associated with future stroke and cognitive decline.  The prevalence of SBI increases with 
age, and may be higher in African Americans.  While the etiology of SBI appears to be 
heterogeneous, thrombus and hypercoagulability likely play a role.  Sickle cell anemia is a 
known risk factor for SBI.  While SBI is the most common neurological manifestation 
affecting children with SCA, its prevalence in adults with SCA is not well defined.  
Furthermore, no published studies have examined the associations between SBI and the 
heterozygous form of sickle cell anemia, SCT. 
5. WHITE MATTER LESIONS 
5.1 Overview 
The central nervous system is divided into white and gray matter (Figure 12).  White 
matter owes its whitish color to myelin sheaths, lipid and protein coverings surrounding the 
neuron axons2.       The function of myelin sheaths is to insulate the axons and increase the 
speed of action potentials, or nerve impulses2.   In the central nervous system, myelin sheaths 
are produced by oligodendrocytes, a type of glial cell2.  Leukoaraiosis, also called white 
matter lesions (WML), are diffuse areas of the cerebral white matter characterized by loss of 
oligodendrocytes, axon demyelination, formation of vacuoles within and adjacent to the 
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neurons, and spongiosis, or intercellular edema106.  In epidemiological studies, WML are 
primary detected by MRI, using proton density imaging.  The severity of WML is typically 
estimated by the extent of WML, graded either qualitatively by comparison to reference 
images, or volumetrically.   Intra-reader reproducibility of qualitative scores range from 71% 
- 94.5%, while inter-reader agreement ranges from 68% - 92%67, 72.  The validity of MRI-
detected WML is generally not ascertained, as this would require post-mortem examination. 
5.2 Etiology of White Matter Lesions 
 Hypoperperfusion and ischemia are thought to cause oligodendrocyte cell death and 
resulting WML107.  The deep white matter is particularly vulnerable to ischemia and 
hypoperfusion.  Its network of small penetrating arteries and arterioles has a poor 
anastomatic system of collateral vessels, supplied solely by the leptomeningeal arteries107, 108.  
In animal experiments, cerebral ischemia induced in gerbils109 and rats110 has been shown to 
result in WML.  While animal studies are not always generalizable to humans, human brain 
autopsies have confirmed a 20% decreased concentration of arterioles and afferent capillaries 
within white matter lesions, compared to healthy white matter tissue106.  Loss of 
microvasculature may result from chronic ischemia inducing endothelial cell apoptosis.  
However, to date, autopsies have not identified the source of cerebral ischemia putatively 
causing WML107.  
5.3 Prevalence of White Matter Lesions 
 In elderly populations WML are particularly prevalent, with a greater severity 
observed in African Americans.  During the ARIC study baseline MRI exam, WML were 
detected in 86% of individuals aged 55 – 72.  This is consistent with baseline estimates from 
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the Cardiovascular Health Study, which reported a WML prevalence of 87% in participants 
aged 65-95.   In the ARIC study, the prevalence of WML was found to be slightly lower in 
African Americans than European Americans (81% vs. 91%); however the severity of WML 
in African Americans was greater.  After adjusting for age, the prevalence of severe WML in 
African Americans was 14%, higher than the prevalence observed in European Americans 
(11%).  When examined longitudinally over a 10 year interval, African Americans were also 
more likely to experience worsening of WML severity by at least one grade, from the 
baseline MRI exam until follow up.  In the ARIC study, WML worsening was detected in 
70% of African Americans, compared to 54% of European Americans.    
5.4 Risk Factors of White Matter Lesions 
 Vascular risk factors appear to be strongly associated with leukoaraiosis.  In the 
ARIC baseline MRI, hypertension was noted in 65% of participants with severe WML, 
compared to 43% of participants without WML111.  Participants with severe WML had a 
mean systolic blood pressure of 136 mmHg, significantly higher than 124 mmHg, the mean 
systolic blood pressure observed in participants without WML (p for trend < .0001) 111.  
When examined longitudinally over a 10 year interval, a 1-standard deviation increase in 
mean arterial blood pressure only marginally influenced the odds ratio of increased WML 
severity grade113.  However, when stratified by race, midlife systolic blood pressure was a 
significant predictor of WML progression in African Americans67 .  Cross-sectionally, 
smoking status has also been implicated as a risk factor for WML severity.  At the baseline 
ARIC MRI exam, the prevalence of moderate or severe WML among current smokers was 
43%, compared to 33% in never-smokers (p for trend <.001) 111.  Although it has been 
examined, diabetes mellitus has not been shown to be associated with WML in the ARIC 
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study, either cross-sectionally or longitudinally; however a 1-standard deviation increase in 
fasting glucose was found to significantly increase the odds ratio of WML severity 
progression113.  Thus, vascular risk factors, and possibly diabetes, may be related to the 
etiology of WML. 
5.5 Sickle Mutation and White Matter Lesions 
 In cross-sectional studies, WML prevalence has been associated with both the 
homozygous and heterozygous sickle mutation, which may be a genetic risk factor for 
leukoaraiosis.  White matter lesions were detected in 15% of patients with sickle cell anemia, 
compared to 7% of age, sex, and education matched African American controls with normal 
hemoglobin, in a cross sectional study with a mean study population age of 32 years102.   
Although only one study has been conducted, a greater prevalence of WML has also been 
observed in SCT carriers.   In a small case-control study with 26 participants, children with 
SCT and sibling controls with normal hemoglobin were prospectively screened by brain 
MRI.  White matter lesions were detected in 10% of participants with SCT, but in none of the 
sibling controls51.  The prevalence and severity of WML in adults with SCT is unknown. 
5.6 Burden Associated with White Matter Lesions 
 As with subclinical brain infarctions, WML are generally asymptomatic; however, 
severe WML and progression of WML severity have been shown to predict adverse 
neurocognitive outcomes114-117.  The Leukoaraiosis and Disability Study (LADIS), a 
European multicenter collaboration including 639 patients aged 65-84 with mild cognitive 
complaints, found that severe WML at baseline independently predicted disability, dementia, 
and cognitive impairment114.  After 3 years of follow up, progression of WML severity 
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correlated with a decrease in executive function, assessed by the Vascular Dementia 
Assessment Scale (VADAS) and Stroop test115.  However, the LADIS study may not 
represent the general population of elderly adults, as mild cognitive impairment was an 
inclusion factor for participants.  The Cardiovascular Health Study examined older adults 
using a less restrictive study population.  As with the LADIS study, CHS reported adverse 
outcomes associated WML progression, which was detected by 2 MRI exams performed 5 
years apart.   A progression in WML severity was associated with decreased cognitive 
function, assessed by the Mini-Mental State exam and Digit-Symbol Substitution test116.  
WML progression was also found to predict future stroke in the CHS study.  After 9 years of 
follow up from the second MRI exam, WML severity that worsened by at least one grade 
increased the hazard ratio of stroke by 1.39 (1.02 – 1.88)117.  The observations from the 
LADIS and CHS studies suggest that WML, though often subclinical in presentation, are not 
benign. 
5.7 Summary of White Matter Lesions 
 White matter lesions are very prevalent in elderly populations, and are associated 
with cognitive decline and stroke.  A greater severity, and an accelerated progression of 
WML severity, has been detected in African Americans.  The etiology of WML appears to be 
related to hypoperfusion, but is not well established.  Both sickle cell anemia and SCT have 
been associated with a greater prevalence of WML, when compared to matched controls with 
normal hemoglobin.  However, it is unknown if older adults with SCT have a greater severity 
of leukoaraiosis than African Americans with normal hemoglobin. 
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6. SICKLE CELL TRAIT AND CEREBROVASCULAR DISEASE 
6.1 Overview 
 Sickle cell anemia is a known risk factor for stroke; however, the association between 
SCT and cerebrovascular disease is less well-established.  The published literature entails a 
total of 17 case reports, 3 retrospective studies, and a single, prospective study examining 
SCT and stroke. 
6.2 Case Reports 
 Numerous case reports have described stroke in young patients with SCT, with no 
predisposing cerebrovascular risk factors118-129.  The majority of these cases were not 
preceded by known episodes of hypoxia; however, two describe post-operative stroke in 
children sedated by general anesthesia121, 122.  Necropsy examinations identified sagittal sinus 
thrombosis in both, with perioperative hypoxia assumed to trigger erythrocyte sickling and 
clot formation118-120.   
 Several criticisms of the associations between SCT and stroke have been made.  
Because many of the published case reports antedate modern medical practice, it has been 
suggested that the evaluations of stroke risk factors were incomplete130.  A case report 
describing stroke in a 32 year old with SCT was criticized, due to the presence of 
lymphocytes in the cerebral spinal fluid, which may be suggestive of meningoencephalitis as 
the stroke cause, rather than SCT131.  However, the post-mortem evaluation revealed 
bilateral, old infarctions in the deep white matter, in addition to new infarcts, which 
reasonably may have preceded the infection126.  Another case report, of a 22 year old male 
with SCT, was criticized due to a history of rheumatic fever and mitral valve disease131.  
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However, echocardiography only detected mild mitral valve prolapse and regurgitation, and 
no mention was made of heart failure or left atrial dilation, more widely accepted cardiac risk 
factors for stroke123.  With or without criticisms, case reports are inherently subject to 
publication bias.  They capture attention by describing interesting, medical anomalies, but 
may not accurately reflect population-based associations. 
6.3 Retrospective Studies 
 Three retrospective studies analyzing sickle cell trait and hospital discharge for stroke 
have been published.  The first, conducted from 1965-1969 at North Carolina Memorial 
Hospital, included 227 patients with SCT and 16,701 African Americans assumed to have 
normal hemoglobin.  No differences were found in frequency of hospital discharges for 
stroke; however, this study is deeply flawed.  The African American controls were never 
confirmed to have normal hemoglobin, which may have resulted in substantial 
misclassification bias.  Furthermore, there was no statistical control for age.  While the mean 
age of SCT patients hospitalized with stroke was 38 years, the control group was much older.  
The mean age of the controls is not published; however, 88% were over the age of 30, and 
37% were over the age of 65.  As Steen, et al point out, if the control group is assumed to 
have a prevalence of SCT that is 7.8%, then 1,303 members of this group were unidentified 
SCT carriers51.  A lifetime  stroke incidence among SCT carriers would therefore only need 
to be 8.2% higher than in African Americans with normal hemoglobin, to explain the 107 
excess strokes among the group of African American control group51. 
 The second study, conducted more recently in the French Carribean colony of 
Guadaloupe, analyzed the prevalence of SCT in 295 hospitalizations for stroke.  A 10-fold 
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higher risk for hemorrhagic stroke and a 15-fold lower risk for ischemic stroke were 
observed in patients with SCT, compared to Guadeloupeans with normal hemoglobin132.  
This study has been criticized for diagnosing stroke type by computed tomography, which 
may not distinguish between primary hemorrhages, and hemorrhagic bleeding secondary to 
infarctions133.  It is also uncertain that the population of Guadeloupe can be generalized to 
African Americans, due to differences in genetic ethnography.  The Guadeloupean 
population is primarily multiracial creole, an admixture of European, African, Indian, and 
Amerindian ancestries. 
 Finally, a recently conducted analysis based on 13,964 African Americans (2,642 
with SCT and 139 with SCA) registered with the Kaiser Permanente Northern California 
health system reported no differences in stroke diagnoses for  patients with either SCT, SCA, 
or normal hemoglobin134.  While hemoglobin was ascertained by laboratory analysis, the 
mean age of the study population was 35.  In adult populations, only pregnant African 
American women are routinely tested for sickle hemoglobinopathies, and if positive, the 
fathers are tested as well134.  Due to the young age of the study population and low number of 
ischemic stroke events, the authors concluded the analysis was underpowered to detect 
statistically significant differences in stroke prevalence among patients with SCT, SCA, or 
normal hemoglobin134. 
6.4  Prospective Studies 
 The association between SCT and stroke has been examined in a single, prospective 
epidemiological study135.  In this analysis from the ARIC study, 3,497 genotyped African 
Americans were followed a median of 22 years.  The frequency of ischemic stroke was 
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slightly higher in those with SCT (13%) than participants with homozygous hemoglobin A 
(10%).  In multivariable analyses controlling for the traditional risk factors of stroke, SCT 
was associated with a 40% higher risk of stroke (OR= 1.4, 95% CI: 1.0 – 2.0), and an 
incidence rate difference amounting to nearly 2 extra strokes per 1000 person years (IRD = 
1.9, 95% CI: 0.3 – 3.8). However, this analysis was based on a single cohort study, and 
warrants replication in other populations.  
7. PUBLIC HEALTH IMPLICATIONS  
 African Americans are disproportionately burdened by cerebrovascular disease.  The 
disparities in stroke prevalence, incidence, and associated disability and mortality underscore 
a dire need for effective stroke prevention strategies.  Genetic risk factors may present an 
opportunity to target high risk individuals for prevention.  Approximately 41 million 
individuals living in the United States self-identify as black 136.  With a heterozygous allelic 
frequency of 8%, sickle cell trait is estimated to affect 3.3 million of these individuals.   In 
1978, the National Institute of Health recommended mandatory newborn screening for sickle 
cell hemoglobinopathies137, and by 2006, all 50 states initiated this practice universally138.  
As a result, SCT is easily identifiable, and documented in the medical records of younger 
generation African Americans.  Although somewhat controversial, student athletes are also 
screened for SCT, as mandated by the National Collegiate Athletic Association139.  Three 
branches of the Department of Defense, the US Air Force, US Marines, and US Navy, screen 
for SCT as well140. 
 Environmental exposures and behaviors are known to influence the phenotypic 
expression of SCT.  Heavy exertion, dehydration, and high altitude are widely accepted to 
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invoke hemoglobin S polymerization and erythrocyte sickling in SCT carriers.  Though the 
associations between SCT and stroke have been conflicting in retrospective studies, SCT has 
been associated with stroke in case reports, and a single, prospective study.  A higher 
prevalence of subclinical small vessel disease has also been detected in SCT carriers, in a 
small, pediatric study.  If SCT is indeed associated with stroke and cerebrovascular disease, 
modification of the phenotypic expression, either by behavior, environment, or 
pharmacotherapy, may be tenable for the prevention or treatment of stroke in over 3 million 
African American SCT carriers.    
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CHAPTER 2:  STUDY AIMS AND RATIONALE 
INTRODUCTION 
 Numerous case reports have described stroke in young patients with SCT, with no 
underlying risk factors for cerebrovascular disease.  Additionally, SCT has been associated 
with stroke in a single, prospective epidemiological study.  The pathophysiology of stroke in 
SCT carriers is unclear; however, and may be related to cerebral small vessel disease.  We 
hypothesize that sickle cell trait is associated with an increased risk of cerebral small vessel 
disease.  The hypercoagulability and vasculopathy observed with SCT lend biological 
plausibility to this hypothesis, as both conditions contribute to cerebrovascular disease.  
Previous research examining SCT and small vessel disease is scarce; however, an increased 
prevalence of WML have been noted in SCT carriers, in a small study of pediatric patients.  
We intend to conduct the first population-based, epidemiological investigation of sickle cell 
trait and cerebral small vessel disease.  To accomplish this, we will analyze data from the 
Atherosclerosis Risk in Communities Study (ARIC), which examined a subset of participants 
by cerebral MRI in 1993-1995 and 2004-2006.  Genetic modification by stroke candidate 
genes, sickle haplotypes, and alpha thalassemia will be considered as well.    
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PRIMARY AIM:  Analyze associations between sickle cell trait and the prevalence, 
severity, and progression of white matter lesions in African Americans.   
We hypothesize that African American participants with SCT will have a greater prevalence 
and severity of WML at the baseline MRI (1993-1995), and an increased rate in the 
progression of WML between MRI 1 (1993-1995) and MRI 2 (2004-2006). 
Sub-aim:  Consider potential modification of the SCT and WML associations by 
environmental covariates (traditional risk factors for stroke), and genetic covariates (sickle 
haplotypes, alpha thalassemia, and stroke risk candidate genes). 
 
SECONDARY AIM :  Quantify associations between sickle cell trait and the prevalence and 
incidence of subclinical brain infarctions in African Americans. 
We hypothesize that African American participants with SCT will have a greater number of 
SBI lesions detected at the first MRI (1993-1995), and will develop a greater number of SBI 
lesions by the second MRI screening (2004-2006). 
Sub-aim:  Consider potential modification of the SCT and SBI associations by 
environmental covariates (traditional risk factors for stroke), and genetic covariates (sickle 
haplotypes, alpha thalassemia, and stroke risk candidate genes). 
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CHAPTER 3:  METHODS 
1. INTRODUCTION 
 We investigated the associations between sickle cell trait and cerebrovascular disease in 
African Americans participating in the Atherosclerosis Risk in Communities Study.  The 
ARIC study includes cerebral MRI screenings, extensive genomic characterization, and 
phenotypic data meticulously collected by quality assurance protocols.  The following 
chapter will describe the ARIC study design, sickle cell trait genotyping, imputation of 
potential modifier genes, stroke and TIA diagnoses, magnetic resonance imaging for 
subclinical brain infarction and white matter lesion detection, and clinical covariate data 
collection.  Finally, this chapter will conclude with a detailed description of the statistical 
analyses and power calculations. 
2. STUDY DESIGN 
 The ARIC study is an ongoing, prospective epidemiological cohort study.  A biracial, 
population-based sample (N= 15,792) of African Americans and European Americans aged 
45-65 were recruited at the study onset in 1987-1989141.  Participants were recruited from 
Jackson, Mississippi; Forsyth County, North Carolina; Washington County, Maryland; and 
Minneapolis, Minnesota.   African Americans (N=4,270) were selected from the Jackson and 
Forsyth sites, representing urban, suburban, and rural areas.  Households in Forsyth County 
were identified for study inclusion by area sampling, while driver’s licenses listings were 
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used to identify age-eligible residents in Jackson142.  The cohort participation rate among 
African Americans was 46%; but participants did not differ from nonresponders in general 
health status or hospitalizations141.  The ARIC study includes 5 cohort examinations (visit 1: 
1987-1989; visit 2: 1990-1992; visit 3: 1993-1995; visit 4: 1996-1998; and visit 5: 2011-
2013), annual telephone surveys during interim years, and ongoing surveillance of 
hospitalized events.  Brain MRI was offered to a random subset of participants in 1993-1995, 
with a follow up exam offered in 2004-2006.  There were 926 African Americans 
participating in the first MRI exam, with 470 (56%) returning for the second MRI.  
3. SICKLE CELL TRAIT GENOTYPING 
 SCT was genotyped in consenting African Americans using a TaqMan® SNP 
Genotyping Assay (Applied Biosystems; Foster City, CA).  TaqMan® high throughput 
assays genotype polymorphisms of interest using polymerase chain reactions and dye-labeled 
probes143.  First, the DNA is denatured by heating, allowing the double stranded helix to 
separate.  Once denatured, a primer sequence of the DNA binds to catalytic enzymes, or 
polymerases, which initiate replication.  Genotypes are revealed by dye-labeled probes, with 
DNA sequences complementary to the polymorphism of interest.  The 5’ ends of the probes 
contain reporter dyes, while the 3’ ends are bound to quenchers.  The quenchers absorb the 
fluorescent energy of the reporter dyes, as long as the probe is intact and bound to the DNA.  
Probes are released from the DNA by the polymerase Taq, as it synthesizes new strands.  
Fluorescence is then detectable by laser excitation.  The fluorescent signals are plotted and 
measured with sequence detection software, allowing allelic discrimination143.  
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  Assay reproducibility is validated by genotyping blinded duplicates, or by assaying 
positive controls, DNA samples with known genotypes determined by a different method143.  
The ARIC central laboratory performs blind replicate redundancy tests in randomly selected 
samples, representing 5% of the total assays.  If discordant genotypes are detected in more 
than 2%, SNPs are excluded from further analysis.  In addition to these quality control 
measures, we will assess genotyping errors by Hardy-Weinberg equilibrium (HWE) testing 
144.  In large, randomly mating populations without selection, genetic drift, genetic mutation, 
or gene flow, allelic frequencies will remain constant from one generation to the next145.  
While no population strictly meets Hardy Weinberg assumptions, wide deviations from the 
expected genotype frequencies often indicate genotyping errors.  However, genes with a 
minor allele frequency less than 5% may not follow Hardy Weinberg proportions144, a 
potential consideration in our analysis. 
4.  GENETIC MODIFIERS 
 Potential genetic modifiers of the association between SCT and cerebrovascular 
disease were genotyped or imputed, by a variety of methods.  Hemoglobin C was genotyped 
by Taqman, as previously described.  The Affymetrix 6.0 GWAS Array, which 
simultaneously types 906,600 variants in the coding and noncoding regions of the DNA146, 
was used to genotype common SNPs.  Rare variants were genotyped by the Affymetrix 
Axiom Exome Chip Array, simultaneously typing 300,000 coding SNPs within the exons.  
The GWAS and exome chip arrays function similarly, but target different SNPs.  Arrays are 
divided into multiple wells, or features, each containing a specific probe complementary to a 
particular SNP.  Prior to genotyping, the sample DNA is digested by restriction enzymes 
(Nsp I and Sty I), and DNA fragments are ligated to adaptors146.  DNA primers recognize the 
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adapter sequences, and initialize amplification by polymerase chain reactions.  Once the 
DNA is amplified, it is fragmented and labeled with biotin146.  The biotin-labeled DNA is 
then washed over the array for 14-16 hours.  Available SNPs bind to the complementary 
probes, and are identified by laser fluorescence.     
 Genetic markers typed by the GWAS chip were used to impute additional SNPs, 
based on the 1000 Genomes reference panel.  The 1000 Genomes Project sequenced the 
entire genome of 2500 individuals of Chinese, Japanese, Indian, African, European, and 
Latin American ancestries.  The initial phase included low coverage (~4x) whole genome 
sequencing, followed by moderate coverage (~20x) whole exome sequencing, and finally 
high coverage (~40x) sequencing in 500 individuals, as technology advanced and costs 
decreased147.  Genotype data in the 1000 Genomes Project is much denser than commercially 
available GWAS or Exome chips, and can be used as a reference for Monte Carlo Markov 
models, which impute untyped SNPs, based on known linkage disequilibrium patterns.  
However, imputed data is highly dependent on the sample from which it is imputed, and 
ethnic match must be considered148.  In the ARIC Study, SNP imputations in African 
Americans have been shown to have better accuracy with the 1000 Genomes reference 
panels, compared to the HapMap III panels, which were based on a sample with less ethnic 
diversity149.   
 GWAS data were subjected to rigorous quality control.  Duplicate samples were 
identified by PLINK software, and removed from analysis.  Individuals with >5% missing 
genotype calls out of the total number of SNPs typed were also removed, as this may indicate 
a genotyping problem that affects all SNPs for this individual148.  As a simple test to rule out 
sample mix-ups, the concordance between self-reported gender and genotyped sex were also 
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assessed, using PLINK, and discordant individuals were removed.  First degree relatives 
were also identified by PLINK, defined by alleles that were identical by state and had a 
distance value of ≥ 0.8.  Race-specific imputation quality was ascertained by the squared 
Pearson correlation (r2) between the imputed genotype calls and the true genotype150.  An r2 
value of .90 or greater was considered sufficient for inclusion in the analysis.  Quality scores 
for hemoglobinopathies, stroke modifier SNPs, and sickle haplotype proxies are shown in 
Tables 2, 3, 4, and 5. 
Table 2:  Imputation quality scores for hemoglobinopathy modifier genes 
 
Gene Gene Name Effect SNPs MAF Affy 6.0 r2 
HBB Hemoglobin, beta Beta thalassemia 
Beta thalassemia 
Senegal Haplotype 
-88 (C-T) 
-29 (A-G) 
rs7482144 
 ----- 
----- 
----- 
HBA1 Hemoglobin, alpha 2 Alpha thalassemia rs63751476  ----- 
HBS1L-MYB Intergenic region Increase gamma globin rs9399137 0.753 0.991 
BCL11A B-cell lymphoma Increase gamma globin rs766432 0.074 0.986 
 
The majority of hemoglobinopathy modifiers were not imputable, using the Affymetrix 6.0 
microarray and 1000 Genomes reference panel.  However, SNPs for the HBSIL-MYB and 
BCL11A genes, which are external to the HBB gene-like cluster and influence gamma globin 
production (and fetal hemoglobin concentrations), imputed with high quality. 
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Table 3. Imputation quality scores for SCA stroke risk candidate genes 
 
Gene Gene Name SNPs MAF Affy 6.0 r2    
ADCY9 Adenylate cyclase 9 rs2072338  
rs437115  
rs2238432  
rs2238426  
rs2283497 
.167 
.475 
.261 
.149 
.457 
0.825 
0.963 
0.928 
0.926 
0.779 
  
ANXA2 Annexin a2 rs11853426  -----   
BMP6 Bone morphogenic  
protein 6 
rs267196  
rs408505 
rs267201 
rs449853 
.299 
.663 
.345 
.411 
1.0 
1.0 
0.994 
0.987 
  
CCL2 Chemokine ligand 2 rs4586  -----   
CSF2 Colony stimulating 
factor 2 
rs25882 .31 0.976   
ECE1 Endothelin converting  
enzyme 1 
rs212528 
rs212531 
.108 
.098 
1.0 
0.991 
  
ERG V-ets virus e26 
oncogene like 
rs989554 .722 0.978   
MET Met proto-oncogene rs38850 
rs38859 
.053 
.09 
0.975 
0.997 
  
SELP Selectin P rs2420378  
rs3917733  
rs3753306 
.114 
.075 
.53 
1.0 
0.996 
0.944 
  
TEK Tek tyrosine kinase rs489347 .68 1.0   
TGFBR3 Transforming bone 
growth  
factor β-receptor III 
rs2148322  
rs2765888  
rs2007686  
rs284875 
 
.118 
.149 
.903 
----- 
0.991 
0.993 
0.99 
  
TNF-α Tumor necrosis factor rs1800629 .135 0.99   
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With the exception of ANXA2 and CCL2, all SCA stroke risk candidate genes were imputable 
to the 1000 genomes reference panel, and most were high quality imputations.   Stroke risk 
SNPs with genome-wide significance in large consortia of Europeans were also examined, 
and shown to impute very well. 
Table 4. Imputation quality scores for stroke risk candidate genes with genome-wide 
significance 
 
Gene Gene Name SNPs MAF Affy 6.0 r2 
HDAC9 Histone deacetylase 9 rs2107595 
rs11984041 
0.219 
0.224 
0.978 
0.974 
PITX2 Paired-like homeodomain 2 rs6843082 0.691 1.0 
NINJ2 Ninjurin 2 rs12425791 0.107 1.0 
 
When SNPs could not be imputed by the Affymetrix 6.0 GWAS chip and 1000 Genomes 
reference panel, the exome chip genotypes were searched.  However, none of the missing 
SNPs were identified by the exome chip.  After concluding that SNP data were not available, 
proxies for SNPs were identified using PLINK.  Proxy SNPs were identified by linkage 
disequilibrium, using publically available data from the 1000 Genomes project.  SNP proxies 
with a correlation of .80 or greater were considered acceptable.  Imputation quality scores for 
Senegal haplotype proxies were assessed, using the GWAS chip and 1000 Genomes 
reference panel.   
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Table 5:  Imputation quality scores for Senegal haplotype proxies 
 
Gene Effect SNP Proxy SNPs Proxy r2 MAF Affy 6.0 r2 
HBB  
 
Senegal  
Haplotype 
 
rs7482144 rs10128556 
rs2071348 
rs2855039 
rs2855121 
rs145323148 
11:5289228 
rs72872549 
0.890995 
0.890995 
0.890995 
0.890995 
0.827691 
0.827691 
0.827691 
0.155 
0.155 
 
0.156 
0.164 
0.165 
0.164 
0.971 
0.971 
 
0.977 
0.963 
0.965 
0.969 
 
Several proxies for the Senegal haplotype were identified, but unfortunately, the alpha 
thalassemia deletions were not imputable, or in linkage disequilibrium with any proxy.  
However, whole genome sequencing data is expected to be available soon. 
5. STROKE AND TIA DIAGNOSIS 
 Stroke prevalence was determined in the ARIC study at the baseline visit (1987-
1989)64.  Participants self-reported neurologic signs and symptoms of stroke using a 
validated questionnaire.  The questionnaires were administered by certified interviewers, and 
quality assurance was ascertained by audiotape.  Participants were asked if they had ever 
been told by a physician that they had a stroke or TIA, or had experienced sudden episodes of 
speech dysfunction, vision loss, double vision, weakness or paralysis, numbness or tingling, 
or dizziness and loss of balance.    Based on the questionnaire responses, a computer 
algorithm diagnosed stroke and TIA, and determined the vascular distribution involved.   
Stroke symptoms resolving in less than 24 hours were considered TIA.  The standardized 
questionnaire and computer algorithm used by the ARIC study were previously validated in 
the Asymptomatic Carotid Atherosclerosis Study (ACAS).  When compared to a 
standardized neurological exam by a neurologist, diagnosis agreement with the computer 
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algorithm was 80.1%.  Overall, the computer algorithm classified stroke and TIA with a 
sensitivity of 87.8% and a specificity of 71.9%151.  
 Stroke incidence was determined in the ARIC study by annual telephone contact with 
the participants, surveillance of hospitalized events, and death records60.  Discharge lists for 
hospitalized study participants with ICD-9 diagnosis codes 430-438 were provided to the 
ARIC study.  When keywords indicative of stroke were present in the discharge summaries, 
the medical records were abstracted60.  Stroke diagnosis was determined by computer 
algorithm and physician review of the medical record, which included the discharge 
summary, imaging reports, neurological consults, and medical history.  Discrepancies 
between diagnoses made by the physician reviewer and computer algorithm were settled by a 
second physician adjudicator.  Agreement rates between the physician reviewer and 
computer algorithm were 78%60.  In the majority of discordant diagnoses (65%), the 
physician adjudicator agreed with the physician reviewer, rather than the computer 
algorithm60.  Based on the clinical picture, stroke was classified as either definite or probable, 
and categorized as thrombotic, cardioembolic, lacunar, subarachnoid hemorrhage, or 
intracerebral hemorrhage (Table 8).  Stroke symptoms resolving in less than 24 hours were 
considered TIA.  Stroke was considered “possible”, rather than “definite” or “probable” 
when there was a clinical presentation of at least one major symptom (hemiparesis, 
homonymous hemianopia, or aphasia), or at least two minor symptoms (diplopia, vertigo, 
dysarthria, dysphagia, or dysphonia, unilateral numbness, severe headache, depressed 
consciousness, meningeal irritation, retinal hemorrhage, or palsy of the iii cranial nerve), but 
the clinical history, imaging reports, or autopsy were inconclusive.  Neurological symptoms 
attributable to head trauma, neoplasm, coma (due to diabetes, epilepsy, poisoning / drug 
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overdose, hypovolemia, hypoglycemia, uremia, or liver disease), cerebral vasculitis (due to 
systemic lupus erythematosus, or radiation), peripheral neuropathy, bleeding disorders 
(disseminated intravascular coagulopathy or thrombocytopenia), or central nervous system 
infection involving the brain or meninges were considered ineligible for stroke diagnosis.    
Table 6:  Definite and Probable Stroke subtype classification 
Stroke Subtype Definite Diagnosis Probable Diagnosis 
Subarachnoid 
Hemorrhage 
1.  Identification by Angiogram  
     + Bloody spinal fluid 
2.  Identification by CT or MRI 
3.  Identification by surgery 
4.  Identification by autopsy 
1.  Identification by Angiogram 
     * Spinal tap not done 
2.  Symptoms (1 or more): 
        Severe headache 
        Depressed consciousness 
        Meningeal irritation 
        Retinal hemorrhage 
      + Bloody spinal fluid 
Brain Hemorrhage 1.  Identification by CT or MRI 
2.  Identification by surgery 
3.  Identification by autopsy 
4.  Major symptom (1) 
        Hemiparesis 
        Homonymous hemianopia 
        Aphasia 
      + Bloody spinal fluid        
5.  Minor symptoms (2) 
        Diplopia 
        Vertigo / Gait disturbance 
        Dysarthria, dysphagia, or    
           Dysphonia 
         Unilateral numbness      
      + Bloody spinal fluid        
1.  Major symptoms (1) 
        Hemiparesis 
        Homonymous hemianopia 
        Aphasia 
2. Minor symptoms (2) 
        Diplopia 
        Vertigo / Gait disturbance 
        Dysarthria, dysphagia, or 
Dysphonia 
         Unilateral numbness   
3.  Coma persisting 24 hours 
      + Bloody spinal fluid 
* CT / MRI not done or            
        inadequate 
Thrombotic Brain 
Infarction 
1.  Identification by autopsy 
2.  Major symptom (1) 
        Hemiparesis 
        Homonymous hemianopia 
        Aphasia 
      + MRI / CT identification 
3.  Minor symptoms (2) 
        Diplopia 
        Vertigo / Gait disturbance 
        Dysarthria, dysphagia, or    
           Dysphonia 
         Unilateral numbness      
      +  MRI / CT identification 
1.  Major symptom (1) 
        Hemiparesis 
        Homonymous hemianopia 
        Aphasia 
2.  Minor symptoms (2) 
        Diplopia 
        Vertigo / Gait disturbance 
        Dysarthria, dysphagia,               
Dysphonia 
         Unilateral numbness     
* CT / MRI not done or            
        Inadequate 
* Spinal tap not done 
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Embolic Brain 
Infarction 
(Non-carotid) 
1.  Identification by autopsy 
       Brain infarction 
       + Emboli in any organ 
2.   Major symptom (1) 
        Hemiparesis 
        Homonymous hemianopia 
        Aphasia 
        + Valvular heart disease;   
          Atrial fibrillation, MI,   
          Cardiac surgery, myxoma 
        + Identification by MRI / CT 
3.  Minor symptoms (2) 
        Diplopia 
        Vertigo / Gait disturbance 
        Dysarthria, dysphagia, or    
           Dysphonia 
         Unilateral numbness      
        + Valvular heart disease, 
           Atrial fibrillation, MI,   
           Cardiac surgery, myxoma 
        + Identification by MRI / CT 
1.  Major symptom (1) 
        Hemiparesis 
        Homonymous hemianopia 
        Aphasia 
        + Valvular heart disease,  
           Atrial fibrillation, MI,   
          Cardiac surgery, myxoma 
2.  Minor symptoms (2) 
        Diplopia 
        Vertigo / Gait disturbance 
        Dysarthria, dysphagia, or    
           Dysphonia 
         Unilateral numbness      
        + Valvular heart disease,  
           Atrial fibrillation, MI,   
           Cardiac surgery, myxoma 
* Inconclusive MRI / CT 
* Spinal tap not done 
 
 
6. MAGNETIC RESONANCE IMAGING PROTOCOL 
  Brain MRI was offered twice in the ARIC study:  in 1993-1995 and 2004-2006.  All 
exams were performed by certified radiographers following standardized protocols, and read 
by board-certified radiologists with subspecialty training in neuroradiology.  Quality 
assurance was ascertained by intra- and inter-reader agreement among randomly replicated 
images.  Scanner performance and resolution were monitored by phantom images submitted 
bi-monthly.  Cerebral images were acquired using the anterior commissure / posterior 
commissure (ACPC) line as an anatomic reference.  First, the ACPC line was located in the 
sagittal view (sectioning the brain into left and right).  Axial views (sectioning from top to 
bottom) were then acquired by aligning images parallel to the ACPC.  Contiguous axial 
images were captured in 5 mm slices, from the vertex of the skull to the base, using General 
Electric 1.5 Tesla scanners.   Proton density (sometimes called spin density) weighting was 
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achieved by setting the repetition time to 3000 ms and the echo time to 30 ms.  T2 weighted 
images were acquired with a 3000 ms repetition time and a 100 ms echo time, and T1 
weighted images used a 500 ms repetition time and a 20 ms echo time.  Imaging protocols 
and equipment remained consistent between MRI 1 and MRI 2 with the exception of axial 
FLAIR, added to MRI 2 after software upgrades.    
7. SUBCLINICAL BRAIN INFARCTIONS 
Lacunes were identified in the cortical gray matter and deep nuclear regions by signal 
hyperintensities using T1 and T2 weighted MRI, and in the white matter and brain stem by 
hypointensities in T1-weighted images.  Focal, non-mass lesions measuring 3 – 20 mm 
within territories of vascular distributions were considered SBI when asymptomatic, in 
individuals without prevalent or incident stroke or TIA prior to cerebral MRI.  SBI diameters 
were measured by electronic calipers, using the largest dimension within the contiguous MRI 
slices.  Inter- and intrareader agreement rates among ARIC neuroradiologists were 79% and 
82%, respectively71.  Periventricular spaces, which fill with cerebral spinal fluid, are often 
indistinguishable from lacunes when imaged by MRI without FLAIR.  To avoid false 
positive identification of SBI, lesions less than 3 mm in diameter were considered 
perivascular spaces.  Although signals from cerebral spinal fluid were filtered by FLAIR in 
the second MRI exam, lesions less than 3 mm remained classified as perivascular spaces, for 
consistency of definitions. 
8. WHITE MATTER LESIONS 
Leukoaraiosis was defined by diffuse areas of white matter hyperintensities, detected 
by proton density imaging.  For the purposes of our analysis, WML were considered 
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subclinical, when identified in individuals without prevalent or incident stroke or TIA prior 
to MRI examination.  Severity was graded qualitatively by neuroradiologists, by matching 
lesion patterns to reference images112.  The reference images ranged from a few “dots” of 
hyperintensities within subcortical white matter, to continuous periventricular rims of 
hyperintense regions, to confluent periventricular regions involving the entire white matter72.  
Inter- and intra-reader reliability coefficients in the ARIC study were .68 and .71, 
respectively72. 
9. COVARIATE ASSESSMENT 
      The analysis of SCT and cerebrovascular disease accounted for ancestry, as well as 
confounding by the traditional risk factors of stroke: age, sex, smoking, hypertension, 
hyperlipidemia, diabetes, coronary heart disease, and atrial fibrillation.  Clinical covariates 
were ascertained during the baseline ARIC exam (1987-1989), by home interviews, health 
questionnaires, and clinical examinations.  Causal pathways between confounders, SCT 
expression, and cerebrovascular disease are shown in Figures 15 and 16. 
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Figure 4:  Directed acyclic graph for causal pathway between SCT, hypercoagulability, and 
cerebrovascular disease 
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Figure 5:  Directed acyclic graph for causal pathway between SCT, vasculopathy, and 
cerebrovascular disease  
 
 
 
   
9.1  Ancestry 
 Hypothetically, if SCT is more prevalent among certain subpopulations of African 
Americans than others, and genetic factors putatively increasing stroke risk are also more 
prevalent among certain subpopulations, then SCT will appear to be associated with 
cerebrovascular disease, simply due to confounding by the population structure. To avoid 
false positive association, population stratification was accounted for with principal 
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components, previously derived by the ARIC Study using EIGENSTRAT software.   
Principal components are continuous axes of genetic variation, or eigenvectors of the 
covariance matrix between samples152.   The first principal component is the eigenvector 
explaining most of the genetic variability.  The second principal component is the 
eigenvector that is orthogonal to the first principal component152.  Frequently, the first and 
second principal components correspond to geographic axes, such as latitude and longitude, 
which have influenced human genetic variation148.  In the ARIC Study, 10 principal 
components capturing population stratification among African Americans have been 
identified.  Individuals with values less than or greater than 8 standard deviations for any 
principal component were considered outliers, and removed from the analysis. 
9.2 Smoking 
 Smoking habits were assessed by interview, recording the amount and duration of 
tobacco use.  Smoking will be dichotomized into a yes/no variable, based on current smoking 
at the baseline visit.  Cotinine and carbon monoxide, metabolites of smoking, are often used 
to validate self-reported smoking.  While this was not ascertained in the ARIC study, a meta-
analysis of 26 studies validating self-reported smoking (as a yes/no variable) with biomarkers 
yielded an overall sensitivity of 87.5% and a specificity of 89.9%153.  Interviewer-
administered questionnaires and observational studies had higher estimates of sensitivity and 
specificity than self-administered questionnaires and interventional studies153.  Retrospective 
measures of smoking, such as pack-years, are sometimes validated by test-retest surveys154; 
however, comparisons with gold-standard biomarkers of smoking are not possible, making 
them potentially less reliable measures. 
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9.3  Blood Pressure 
 Seated blood pressures were measured by random-zero mercury manometers, after 
determining proper cuff sizes based on arm diameters.  A total of 3 measurements were 
made, with only the second and third recorded for analysis.  Hypertension was defined by the 
criteria established by the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood pressure.  For our analysis, a systolic blood pressure exceeding 
140 mmHg, diastolic blood pressure exceeding 90 mmHg, or use of antihypertensive 
medications was considered hypertension.  
9.4  Cholesterol    
 Blood was drawn in EDTA tubes, and shipped to the ARIC Central Lipid Laboratory.  
Cholesterol was measured by an automated process, using an automatic pipetting station and 
a self-contained centrifugal analyzer with an optical monochromator.    Hypercholesterolemia 
was considered a total cholesterol exceeding 240 mg/dL, based on the established guideline 
set by the third report of the National Cholesterol Education Program expert panel on 
detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment 
Panel III), or use of lipid lowering medicines.  ARIC participants were instructed to fast 12 
hours prior to their study visits, yet this was not always achieved.  To avoid misclassification 
bias, blood labs from participants who were not fasting 12 hours will be excluded from the 
analysis 
   Laboratory quality control was ascertained by control samples with known 
concentrations of analytes, which were measured with each run.  Within-day and overall 
precision were calculated by the standard deviation of the control sample’s measured values.  
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Control sample standard deviations were normalized to the mean, to calculate the coefficient 
of variation. 
Coefficient of Variation (CV) = σ / μ 
The coefficient of variation allows direct comparison of the precision of one analytical test to 
another, and is used to assess the reliability of repeated tests.  While the ARIC protocols 
specify quality control and coefficient of variation calculations for lipid labs, these values are 
nowhere to be found on the website.  Further inquiry is underway.   
9.5  Diabetes 
 Blood glucose was measured by the ARIC Central Chemistry Laboratory.  Quality 
control was ascertained by control samples, and the coefficient of variation was calculated to 
be 2.9%.  For the purposes of our analysis, diabetes will be defined by a fasting plasma 
glucose level exceeding 126 mg/dL, the established guideline set by the American Diabetes 
Association157, self-reported diabetes, or use of diabetic medications.  While all ARIC 
participants were instructed to fast 12 hours prior to their study appointments, many were 
found to be noncompliant on the day of their visits.  To avoid measurement bias, lab results 
from patients who did not fast 12 hours were excluded from the analysis.   
9.6  Coronary Heart Disease 
 Prevalent coronary disease was defined by a history of myocardial infarction, 
coronary artery bypass graft, percutaneous coronary intervention, or electrocardiogram 
(ECG) suggestive of myocardial infarction.  A standardized, 12-lead ECG and 2-minute 
rhythm strip were performed at the baseline visit, capturing leads I, II, III, aVR, aVL, aVF, 
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and the precordial leads V1 through V6.  Digital ECG tracings were sent electronically to the 
ARIC ECG Computing Center for analysis, and assigned a Minnesota code158.  ECGs with 
Minnesota codes indicative of myocardial infarction (ST elevation or depression, or inverted 
T-waves), were visually inspected and adjudicated by the Minneapolis ECG Reading Center.  
The agreement between myocardial infarction diagnoses made by Minnesota coding and 
ECG visual inspection is not readily available in ARIC, but has been assessed in a random 
sample of 768 patients, and  reported to be 94.3%159. 
9.7 Atrial Fibrillation 
 Atrial fibrillation was classified by an ECG with a Minnesota code of 8.3158.  
Agreement between Minnesota coding and atrial fibrillation diagnosis by visual inspection of 
the ECG was not ascertained in the ARIC study, but has been previously reported.  In a test 
set of 300 ECGs classified by Minnesota coding and visual inspection by an experienced 
cardiologist, arrhythmia diagnosis agreement was 90%160 
10.  STATISTICAL ANALYSIS 
Associations between sickle cell trait and cerebrovascular disease will be assessed, 
after controlling for ancestry and confounding by the traditional risk factors for stroke (age, 
gender, hypertension, smoking, diabetes, hypercholesterolemia, coronary heart disease, and 
atrial fibrillation)77.  The statistical plans for the WML and SBI aims are shown in Tables 10 
and 11.  Multiple statistical methods were considered for each analysis.  After deliberating 
the pros and cons, a statistical approach was chosen.  The statistical methods are described 
below, along with alternative approaches and the rationale against them.   
 
 67 
 
Table 7:  Statistical plan for white matter lesions aim 
Aim 1 Outcomes Cohort Exams Approach Estimate 
White Matter Lesion  
Prevalence 
MRI 1 Binomial Regression Prevalence Ratio 
White Matter Lesion 
Severity 
 
MRI 1 Multiple linear regression Mean WML severity 
grade 
White Matter Lesion 
Severity Progression 
MRI 1, MRI 2 Analysis of Covariance 
(ANCOVA) 
Mean increase in 
WML severity grade 
 
Table 8:  Statistical plan for subclinical brain infarctions aim 
Aim 2 Outcomes Cohort Exams Approach Estimate 
Subclinical Brain 
Infarction Prevalence 
MRI 1 Multivariable Poisson 
regression 
Prevalence Ratio 
Subclinical Brain 
Infarction Incidence 
MRI 2 Logistic Regression Odds Ratio 
 
10.1.  WML Prevalence 
   The association between leukoaraiosis and SCT status will be assessed at the baseline 
MRI, by dichotomizing WML into a yes / no variable.   Prevalence ratio comparisons will be 
estimated by multivariable binomial regression, adjusted for demographics, traditional stroke 
risk factors, and ancestral principal components: 
ln(P(X)) = α + ∑ [β(SCT) + βi(xi)] 
In this model, the probability of prevalent WML is log transformed, which constrains the 
predicted probabilities to positive numbers.  β(SCT) is the increment to the log-prevalence 
for WML in participants with SCT, compared to those without, after controlling for 
covariates.  The prevalence ratio is calculated by exponentiating β(SCT).  As a derivative of  
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10.1.a.  Alternative Approach 
   As an alternative to prevalence ratios estimated by binomial regression, prevalence 
odds ratios may be estimated, using logistic regression.  Based on previous analyses from the 
ARIC Study, WML are expected to be prevalent in approximately 80% of the study 
population.  Odds ratios are useful for approximating risk of rare events (affecting <10% of 
the population), but overestimates risk when outcomes are common. 
10.2.  White Matter Lesion Severity  
      As shown in Table 9, WML severity scores are designed to represent sequentially 
increasing lesion volumes.  The 10-point scale used to score WML severity will be assumed 
to represent equivalent increments from one grade to the next, and will be modeled as a 
continuous, ordinal variable.   
y = β0 + β(SCT) + βi(xi) 
Where y is the predicted mean score, and the SCT regression coefficient (β) is the difference 
in the adjusted group mean WML score for participants with SCT, compared to those 
without.  Linearity assumptions will be ascertained, with quadratic terms entered into the 
model in the event of non-linearity.  The beta coefficient for the SCT genotype will be 
interpreted as the increase in mean WML score associated with SCT. 
10.3.  White Matter Lesion Progression 
       The change in WML severity score between the first and second MRI exams, will be 
assessed by analysis of covariance (ANCOVA): 
YiMRI2 = β0 + β1YiMRI1 + … + εi 
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Where YiMRI2  is the WML score for subject i at MRI 2 and YiMRI1 is the score at MRI 1.  By 
modeling the WML score at MRI 2 as the dependent variable, and the first WML score as a 
predictor variable, the baseline MRI score becomes an autoregression coefficient161.  This 
overcomes the tendency for regression to the mean, frequently encountered by modeling 
change with simple linear regression: 
Δy = β0 + β(SCT) + βi(xi)+ … 
With regression to the mean, individuals in the higher end of the distribution for WML scores 
at MRI 1 would be less likely to be in the higher end of the distribution of WML scores for 
MRI 2, compared to other study participants.  As a result, the change in WML scores (Δy) 
would be strongly related to the baseline WML score, simply due to chance161.  With 
ANCOVA, change is defined relative to the baseline WML score, to correct for regression to 
the mean161.  Another approach to correct for regression to the mean is to analyze residual 
change, by comparing the observed values of WML scores at MRI 2 to the predicted WML 
scores at MRI 2162.  However, the analysis of residual change (first described by Blomquist 
in 1977) is comparable to ANCOVA. 
   There are some limitations to ANCOVA.  The dependent variable is assumed to be 
normally distributed, and in the event of wide deviation from normality, may require log 
transformation.  ANCOVA also assumes linearity between continuous covariates and the 
dependent variable, and is difficult to interpret when there is interaction between the 
categorical exposure variable and the covariates, making the SCT-stratified slopes 
nonparallel.  Linearity assumptions will be tested by scatter plots, and interaction tested by 
significant cross-product terms.  The time interval between each MRI exam is also assumed 
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to be constant, at 10 years.  However, it is possible that a 10 year interval will not adequately 
describe the time between examinations.  In this case, the actual time variable will be entered 
into the model as a covariate. 
10.3.a.  Alternative Approach 
 As an alternative to ANCOVA, the change in WML severity may be modeled by 
logistic regression or Cox proportional hazards.  This approach has been used on numerous 
occasions in the literature113, 163.  WML progression is dichotomized as either an increase of 1 
or more grade, or the absence of progression.   This dichotomous outcome is then modeled as 
the dependent variable.  It is not clear if this approach accounts for regression to the mean, 
however. 
10.4.  Subclinical Brain Infarction Prevalence 
      The number of subclinical brain infarctions in an individual will be treated as a count 
variable.  Based on previous analyses from the baseline MRI examination in the ARIC study, 
the number of SBI per individual is expected to follow a Poisson distribution68.   
Pr (yi | xi) = exp(-μi)*μiyi  / yi! 
Where y is the observed count, μ is the expected, or mean count, and x terms are the 
exposure and covariate variables164.  Pr(yi | xi) is the conditional probability of the observed 
count, based on the covariate pattern.  Baseline prevalence ratios for participants with SCT, 
compared to those with normal hemoglobin will be analyzed, using Poisson regression: 
log (Yk) = α + β(SCT) + βi(xi) 
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Where Yk is the mean count of a particular outcome, in the exposed or unexposed strata.  
Poisson regression will be used to predict the logarithmic mean count of subclinical brain 
infarctions in participants with and without SCT, controlling for clinical covariates.  The 
prevalence ratio is calculated by exponentiating the regression coefficient β(SCT), and is 
interpreted as the relative increase in number of SBI associated with SCT, compared to study 
participants with normal hemoglobin.  The Poisson distribution will be confirmed with 
goodness of fit statistics, by calculating the deviance to degrees of freedom ratio165.  While a 
deviance/d.f. ratio close to one suggests good fit, a ratio exceeding 1.5 indicates 
overdispersion, leading to estimates with spurious standard errors.  
10.4.a  Alternative Approach 
   As an alternative, prevalence of SBI may be dichotomized as a yes  / no variable, and 
the baseline prevalence difference or prevalence ratios may be calculated, binomial log-risk 
models.  While this is a simpler approach than considering the actual count of SBI, these 
analyses result in loss of information. 
10.5.  Subclinical Brain Infarction Incidence 
 Incident subclinical brain infarction will be defined by new infarctions detected at 
MRI 2 (2004-2006), which were not present at MRI 1 (1993-1995).  Previous analyses of 
incident SBI in the literature have relied on logistic regression, restricting the study 
population to study subjects participating in both MRI 1 and MRI 2116.   
ln [P(X)/(1-P(X)] = α + ∑ [β(SCT) + βi(xi) + …] 
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The dependent variable for the logistic model, or logit, is a log-transformed odds ratio.  The 
SCT beta coefficient describes the increment to the log-odds of incident SBI in participants 
with SCT, taking other covariates into account.  The odds ratio comparing participants with 
and without SCT is estimated by exponentiating the SCT regression coefficient.  Assuming 
the incidence of SBI is low (<10%), the odds ratio can be considered an approximation of 
risk.  Because the time interval between each MRI exam is likely not constant for all study 
participants, the actual time between each exam will be entered as a covariate.  Logistic 
regression assumes continuous variables will be linear on the log scale, and that all covariate 
pairs have multiplicative joint effects.  Linearity assumptions will be verified by plotting 
continuous variable on the log scale, and multiplicativity assumptions tested by entering 
cross-product interaction terms into the model. 
10.5.a.  Alternative Approach 
      As an alternative to logistic regression, incident SBI may be analyzed by Cox 
regression.  The presence of incident subclinical brain infarctions between MRI 1 (1993-
1995) and MRI 2 (2004-2006) would be dichotomized, and hazard ratios will be estimated.  
The hazard ratio is the antilog of the average of differences in log hazards for a particular 
outcome166, and is calculated by Cox regression: 
h(t) = h0 * exp[β(SCT) +  βi(xi)] 
Where h(t) is the hazard function, and h0 is the baseline hazard in unexposed individuals with 
a value of zero for each of the covariates167.  Baseline hazards cancel out in the hazard ratio 
between two individuals, h(t1) / h(t2), written logarithmically as [ log h(t1) – log h(t2) ].  This 
difference in log hazards is averaged across all individuals in the risk set with a particular 
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covariate pattern, and smoothed over time at risk to give the hazard ratio.  Cox regression 
makes no assumptions concerning the survival function, and can be used to model 
continuous, stepwise, parametric, and nonparametric distributions167.  However, as with all 
derivatives of linear models, Cox regression assumes a linear relationship between the 
predictor variables and the log hazard.  Functional forms of predictor variables and linearity 
assumptions will be tested by plotting Martingale residuals, which can be used to reveal 
departures from linearity168.  Cox regression also assumes the hazard ratio for the exposed to 
unexposed individuals remains proportional over time.  Nonproportionality will be assessed 
by plotting Shoenfeld residuals, or by visually inspecting the plots of the negative log of the 
cumulative hazards167.  When the slopes of the negative log cumulative hazards for the 
exposed and unexposed groups cross, proportionality is considered violated.  In this event, 
interaction terms between covariates and time can be entered into the model, or the hazard 
ratio can simply be interpreted as an average effect over the range of times observed167.   
However, Cox regression may not be appropriate for our study design, due to the interval 
censored data and potential for large number of ties, assuming follow-up exams were 
performed over nearly uniform time intervals. 
11. GENETIC MODIFICATION 
   Modification of the associations between SCT and cerebrovascular endpoints by 
traditional stroke risk factors, stroke candidate genes, sickle haplotypes, and alpha 
thalassemia will assessed by exploratory multivariable regression modeling.  Each potential 
genetic modifier will be entered into the regression models separately.  Cross-product 
interaction terms between SCT and potential modifiers will assess interaction on the additive 
scale for ordinary linear regression models, and interaction on the multiplicative scale for 
 74 
 
Poisson models and Cox regression models.  Effect measure modification will be considered 
changes to model variance or the main effect estimate, but will be considered exploratory. 
12.  POWER CALCULATIONS 
 A total of 960 African Americans were examined in ARIC by cerebral MRI.  After 
removing subjects with prevalent stroke / TIA, and accounting for missing covariates or 
principal components, we estimate an effective sample size of 600.   The association between 
SCT and prevalence of WML is not well known.  In a single pediatric study, WML were 
detected in 10% of children with SCT, but in none of their sibling controls with homozygous 
hemoglobin A51.  In the ARIC study, WML were detected in 80.7% of African Americans 
overall111.  Using this as a reference, we expect 80% power to detect a prevalence difference 
of 0.15 in participants with SCT, compared to those without (Figure 17).  While the pediatric 
study may not be directly comparable to older African Americans; the reported effect size 
(prevalence difference of 0.10) is close to 0.15, the effect that our study is powered to 
estimate.   
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Figure 6.  Power calculations for baseline WML prevalence difference associated with SCT status 
To date, the association between SCT and WML severity has been unexplored.  With WML 
severity scored by a continuous, ordinal (0 to 9) scale, with an estimated standard deviation 
of 1111, we expect 80% power to detect a 0.5 difference in mean WML severity score (Figure 
19). 
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Figure 7:  Power calculation for mean WML severity scores, associated with SCT status 
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Abstract 
Background and Purpose:  Cerebral white matter lesions (WML) are associated with 
adverse neurologic outcomes, and have been detected in individuals with sickle cell trait 
(SCT). To date, no large, epidemiological studies have investigated this association. 
Methods:  A population-based sample of African Americans (N=844, mean age=62, 
female=64%) was prospectively imaged by cerebral MRI in 1993-1995 in the 
Atherosclerosis Risk in Communities (ARIC) Study, with 470 (56%) returning for a follow 
up MRI in 2004-2006. Hemoglobin S (rs334) and hemoglobin C (rs33930165) were directly 
genotyped, and participants identified with sickle cell anemia or hemoglobin C excluded. 
WML on MRI were evaluated and scored using a qualitative, 10-point scale. Associations 
between SCT and WML prevalence and severity were analyzed using ordinal logistic and 
linear regression. All models were adjusted for age, sex, smoking, diabetes, hypertension, 
and 10 ancestral principal components. 
Results:  SCT was identified in 56 (6.6%) participants at the baseline MRI.  Individuals with 
SCT had more prevalent (86% vs. 79%), and more severe (mean score 1.5 vs. 1.3) WML 
than individuals without SCT. SCT was associated with a 20% increased odds of WML 
prevalence (POR 1.2, 95% CI: 0.7 – 2.0), and an adjusted mean severity score that was 0.2 (-
0.1 – 0.5) points higher. 
Conclusion:  There was a subtle but insignificant trend for greater WML prevalence and 
severity associated with SCT.  
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Introduction 
 White matter lesions (WML), the result of cerebral small vessel disease, are 
detectable by hyperintensities in the cerebral white matter by MRI. Though often 
unaccompanied by overt neurological symptoms, WML have been shown to predict 
cognitive impairment, dementia, and stroke114-117. In elderly populations, WML are 
particularly prevalent112, with a greater severity observed in African Americans than 
whites111. When examined longitudinally, African Americans appear to have an accelerated 
progression of WML severity as well113.   
 The etiology of WML is believed to be vascular in origin, and possibly related to 
chronic hypoperfusion107. Consistent with this hypothesis, a greater prevalence of WML has 
been observed in patients with sickle cell anemia, a Mendelian hemoglobinopathy 
complicated by microvascular occlusion, hypoperfusion, and heightened stroke risk102. Sickle 
cell trait (SCT), the heterozygous carrier state of sickle cell anemia, is prevalent in 7–9% of 
African Americans and 0.2% of non-Hispanic whites19, affecting over 3 million Americans. 
Though hypoperfusion is not a well-established phenotype of SCT, a greater prevalence of 
WML has been observed in pediatric carriers in a single study51.  Individuals with SCT also 
appear to have increased risk of ischemic strok169, 170.  However, the pathophysiological 
mechanisms of stroke associated with SCT are poorly understood, and may be related to 
cerebral small vessel disease. To date, no large, epidemiological studies have examined the 
prevalence or the progression of WML in African American adults with SCT. We 
hypothesized that SCT would be associated with a greater prevalence, severity, and 
progression of WML in older African Americans imaged prospectively by cerebral MRI in 
the Atherosclerosis Risk in Communities (ARIC) Study.   
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Methods 
  The ARIC study is a biracial, prospective epidemiological cohort based on 4 U.S. 
areas.  Included in this study is a population-based sample (N= 4,270) of African Americans 
aged 45-65 was recruited with informed consent in 1987-1989 from urban, suburban, and 
rural areas of Jackson, Mississippi and Forsyth County, North Carolina.  The ARIC study 
includes 5 cohort examinations spaced approximately 3 years apart (with a larger gap 
between the 4th and 5th visits), with annual telephone surveys during interim years, and 
ongoing surveillance of hospitalized events, and an additional ancillary study visit (the Brain 
MRI visit) in a subset of participants.  All study protocols were approved by the University 
of Mississippi and Wake Forest University Institutional Review Boards.  
 Brain MRI was offered to a random subset of participants in 1993-1995, with a 
follow up ancillary exam offered in 2004-2006.  Standard imaging exclusions included 
metallic implants, aneurysm clips, hearing aids, cardiac pacemakers, spinal cord stimulators 
or other internal electrical devices.  Examinations were performed by certified radiographers, 
using standardized protocols and consistent imaging equipment (GE Signa 1.5 T) for both the 
baseline and follow-up MRI.  Axial images were aligned parallel to the anterior commissure / 
posterior commissure line, and contiguous images were captured in 5 mm slices, from the 
vertex of the skull to the base.  The cerebral white matter was imaged by proton density 
weighting, acquired with a repetition time of 3000 ms and echo time of 30 ms.  All images 
were read by board-certified ARIC radiologists with subspecialty training in neuroradiology.   
Leukoaraiosis was defined by diffuse areas of white matter hyperintensities, and severity was 
graded using a qualitative 10-point scale, by matching lesion patterns to reference images112.  
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The inter- and intra-reader reliability coefficients in the ARIC study were .68 and .71, 
respectively72. 
 For the purposes of our analysis, prevalent stroke was considered a cerebrovascular 
accident occurring prior to the baseline MRI in 1993-1995.   Stroke history was initially 
determined at the ARIC study onset in 1987-1989, by a validated computer algorithm64, and 
thereafter by hospital surveillance with verification by physician review. The diagnostic 
criteria and adjudication have previously been described60.   
   Hemoglobin S and hemoglobin C were directly genotyped, using TaqMan high 
throughput assays, as previously described.  For quality assurance, blind duplicate 
genotyping was performed in a random sample representing 5% of the total assays (kappa 
coefficients 0.83 for hemoglobin S, and 0.93 for hemoglobin C).  In addition to direct 
genotyping, high coverage DNA sequencing was performed.  Any discrepancies were 
identified and adjudicated by review of quality control data and re-genotyping, to yield the 
final hemoglobin S and hemoglobin C classifications. 
 Ancestry was quantified using EIGENSTRAT 5.0.1 (David Reich, open source), 
based on genomic variation characterized by the HumanExome BeadChip v1.0 (Affymetrix, 
Santa Clara, CA), as previously described171.  First degree relatives were identified by 
PLINK (Shaun Purcell, http://pngu.mgh.harvard.edu/purcell/plink)172.  
   Clinical covariates were ascertained at time of the first MRI examination.  Seated 
blood pressures were measured by random-zero mercury manometers.  A total of 3 
measurements were made, with the average of the second and third recorded for analysis.  
Hypertension was considered a systolic blood pressure ≥ 140 mmHg, a diastolic blood 
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pressure ≥ 90 mmHg, or antihypertensive medication use.  Fasting cholesterol and glucose 
were assessed by ARIC central laboratories.  Hypercholesterolemia was considered a total 
fasting cholesterol ≥ 6.2 mmol/L.  Diabetes was defined by either a blood glucose level ≥ 7 
mmol/L, self-reported diabetes, or use of diabetic medications.  Current smoking status was 
determined by self-report. 
Statistical Analysis 
 All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).  Categorical 
variables were compared by a χ2 test, and continuous variables compared by analysis of 
variance.  Categorical variables with expected cell counts < 5 were analyzed using Fisher’s 
Exact test.  Multivariable analyses contrasting SCT with homozygous hemoglobin A (HbAA) 
were adjusted for age, sex, white matter lesion risk factors (smoking, hypertension, and 
diabetes)107, and 10 ancestral principal components.  The association between SCT and 
WML severity score was assessed by linear regression, modeling WML score as a 
continuous, ordinal variable.  After verifying proportional odds, associations between SCT 
and WML prevalence were analyzed by ordinal logistic regression, contrasting a WML score 
of at least 3 to scores of 2, 1, or 0; a score of at least 2 to scores of 1 or 0; and a score of at 
least 1 to a score of 0.  In a subset of study participants returning for the second MRI, 
progression of WML severity score was assessed by linear regression, modeling the change 
in score associated with SCT, with adjustments for age, sex, smoking, hypertension, diabetes, 
and elapsed time between each MRI examination.  Progression of WML was also 
dichotomized and analyzed by logistic regression.  WML progression was considered an 
increase of at least 2 severity points, to minimize the likelihood of spurious progression due 
simply to inaccuracies of the qualitative severity assessment. 
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 Power calculations for difference in WML prevalence and severity score were 
conducted a priori, based on an assumed study population of 800, SCT prevalence of 7%, 
WML prevalence of 80%, and mean WML score standard deviation of 1.0. We expected 
80% power to detect a WML prevalence difference of 14%, and mean WML score difference 
of 0.4, with significance at the α = 0.05 level (2-sided).   
Results 
   A total of 937 African Americans were genotyped for hemoglobin S and hemoglobin 
C, and examined by MRI in 1993-1995.  First degree relatives (n=18), those with missing or 
inadequate genotype calls (n=3), and participants identified with hemoglobin C trait (N=24), 
hemoglobin SC disease (n=1), or sickle cell anemia (n=1) were excluded.  To minimize 
measurement error of WML due to previous stroke, we additionally excluded 26 with history 
of cerebrovascular accident.  After removing subjects with missing clinical covariates (n=18) 
a final study population of 844 remained.   
   Out of 844 African Americans, 56 (6.6%) were identified with SCT.  The mean age at 
the baseline MRI was 62 years, and 64% were women. Study participants with SCT were 
more often men (50% vs. 35%; p=0.02) and less obese (28 kg/m2 vs. 30 kg/m2 BMI; 
p=0.007), with a slightly greater prevalence of current smoking.  (Table 1).   
   White matter lesions were detected in the majority of study participants (80%). A 
greater prevalence was observed in those with SCT (86% vs. 79%; p=0.2) than without SCT, 
yielding an unadjusted prevalence difference of 7% (-0.3 – 16%; p=0.2). Severity scores of 
WML ranged from 0 to 8, with an overall mean score of 1.3 ± 1.2. The mean WML score 
among those with SCT was 1.5 (1.2 – 1.9); slightly higher than the mean score among those 
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with HbAA, 1.3 (1.2 – 1.4). When severity scores were categorized into scores of 1, 2, or 3+, 
a consistent but insignificant pattern of higher WML scores was observed in the group with 
SCT, compared to those with HbAA (Table 2).   
   In multivariable regression analysis controlling for age, sex, ancestry and WML risk 
factors (smoking, hypertension, and diabetes), SCT was associated with a WML mean score 
that was 0.2 (-0.1 – 0.5) points higher than HbAA study participants, but was not statistically 
significant. As shown in Figure 1, the odds of WML associated with SCT were similar 
among differing cut points (contrasting a WML score of at least 3 to scores of 2, 1, or 0; a 
score of at least 2 to scores of 1 or 0; and a score of at least 1 to a score of 0). As a result, we 
present the cumulative POR of 1.2 (0.7 – 2.0) as a summary measure, which takes the 
ordinality of WML scores into account.  
   Of the 844 study participants examined by brain MRI in 1993-1995, 470 (56%) 
returned for the follow-up MRI in 2004-2006.  Within this subset, 36 (7.5%) were identified 
with SCT.  The mean elapsed time between the baseline and follow up MRI examinations 
was 10.8 ± 0.9 years, which did not differ by SCT status (p=0.8). By the second MRI, WML 
prevalence (defined by any score greater than zero) was nearly ubiquitous (100% in 
participants with SCT, and 98% in those with HbAA). The overall mean WML severity score 
was 2.3 ± 1.5, and did not differ by SCT status (p= 0.9). The overall mean increase in WML 
scores between the baseline and follow up scans was 1.1 ± 1.1 points; however, progression 
was marginally attenuated in those with SCT, compared to HbAA participants (0.9 ± 0.9 
points, compared to 1.2 ± 1.1 points, respectively; p=0.1). With WML score change modeled 
as a function of SCT status, adjusted for age, sex, smoking, diabetes, hypertension, elapsed 
time between MRI examinations, and ancestry, SCT was associated with a progression that 
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was 0.3 points lower (95% CI: 0.6 points lower to 0.3 points higher) than those with HbAA.  
When WML progression was analyzed dichotomously, SCT was associated with a 30% 
lower adjusted risk of WML progression (OR = 0.7, 95% CI: 0.3 – 1.5).  Additional analyses 
are shown in Appendix I. 
Discussion 
 At the baseline MRI examination, we observed a subtle, yet imprecise, elevation in 
WML prevalence and severity in study participants with SCT, compared to HbAA 
participants.  The WML prevalence difference, 7%, was lower than our projected power to 
detect a difference of 14%.  Similarly, the adjusted increase in WML score associated with 
SCT, 0.2 points, was less than 0.4 points, the minimum score difference our study was 
powered to detect. Though not statistically significant, there was a consistent pattern of 
increased WML prevalence and severity among those with SCT.  Among the subset returning 
for the follow up MRI, SCT did not appear to be associated with increased progression in 
WML severity; however, estimates were limited by imprecision and small sample sizes.   
Although generally asymptomatic, WML have been shown to predict adverse 
neurocognitive outcomes114-117.  In the Leukoaraiosis and Disability Study, a European 
multicenter collaboration including 639 patients aged 65-84, WML severity independently 
predicted disability, dementia, and cognitive impairment114.  Consistent with this finding, the 
Cardiovascular Health Study, which longitudinally examined WML progression over a 5 
year interval in 1,921 elderly subjects, reported decline in cognitive function and increased 
stroke risk associated with WML progression117.   
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 In cross-sectional studies, both sickle cell anemia and SCT have been associated with 
increased WML prevalence.  In an observational study of 141 young adults with sickle cell 
anemia and 44 age-, sex-, and education-matched African American controls with normal 
hemoglobin, WML were detected in 15% with sickle cell anemia, compared to 7% of the 
controls102.  Though suggestive of an increased risk of WML associated with sickle cell 
anemia, the prevalence difference, 8% (95% CI: -1.4 – 17.6%), was imprecise.  Although to 
our knowledge only one study has been conducted, a greater prevalence of WML has also 
been observed in carriers.   In a small, pediatric case-control study with prospective MRI 
screenings, WML was detected in 10% of children with SCT, but in none of the sibling 
controls51.     
 The etiology of WML remains uncertain, but is thought to be vascular in origin.  The 
deep white matter is particularly vulnerable to ischemia and hypoperfusion.  Its network of 
small penetrating arteries and arterioles has a poor anastomatic system of collateral vessels, 
supplied solely by the cortical and leptomeningeal arteries107, 108.  In animal experiments, 
WML have been induced by eliciting cerebral ischemia in gerbils109 and rats110. While animal 
studies are not always generalizable to humans, human brain autopsies have confirmed a 
20% decreased concentration of arterioles and afferent capillaries within white matter 
lesions, compared to healthy white matter tissue106. The decrease in capillary density may be 
the result of vascular occlusion or chronic ischemia, inducing downstream endothelial cell 
apoptosis by blocking the flow of nutrients173.       
Microvascular hypoperfusion is a known complication of sickle cell anemia, as 
sickled erythrocytes impede flow through the capillary beds, causing vaso-occlusive crises, 
target organ damage, and pain.  Though less established, there is some evidence that carrier 
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status is associated with microvascular hypoperfusion as well.  In the resting state, only 1% 
of erythrocytes in the venous circulation of individuals with SCT are sickled, in contrast to 
30-60% in those with sickle cell anemia10.   However, even in the absence of sickling, blood 
assays of SCT carriers indicate abnormal red cell rigidity174, which may impede the 
microcirculation.  While a capillary lumen diameter typically measures 4-5 μm, red blood 
cells span 8-9 μm175. In order to pass through the capillaries, erythrocytes must be flexible. 
As a possible adaption to diminished red cell flexibility, capillaries in the skeletal muscle of 
individuals with SCT are larger in diameter, but sparser, with an overall reduced surface area 
for gas exchange175. Along with muscle biopsies, hypoperfusion has also been assessed 
indirectly, using the hematocrit to blood viscosity ratio. This index has been observed to be 
reduced in SCT carriers as well174. However, it is unknown if these indices of hypoperfusion 
observed in individuals with SCT indicate hypoperfusion of the cerebral microcirculation.   
We observed an increased frequency and severity of WML in African American 
study participants with SCT, compared to those with HbAA genotypes. However, our 
estimates were imprecise, which may reflect either no association between SCT and WML, 
or deficiencies of the study design. The WML scores were subject to measurement error, 
with an intra-reader reliability coefficient of 0.71. The sample size of participants with SCT 
(N=56) at the baseline MRI was also quite small for an epidemiological study, with an 
attrition rate of 44% by the follow up exam. To overcome the variability inherent with small 
sample sizes, a partnership with other cohort studies examining African Americans by 
cerebral MRI may be worthwhile.  
Additionally, white matter abnormalities associated with SCT may be better detected 
by newer MRI scanners with enhanced resolution. Volumetric analyses of WML have greater 
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reliability than qualitative scoring, improving the precision of the outcome.  Diffusion tensor 
imaging with fractional anisotropy has also been shown to detect subtle white matter 
abnormalities, which were underestimated by conventional imaging of patients with sickle 
cell anemia176, 177.  Fractional anisotropy and volumetric analyses, which will be available in 
the 3rd MRI examination (2011 – 2013) of the ARIC study, may enhance detection of 
possible white matter abnormalities associated with SCT.   
In conclusion, the relation between SCT and WML, if any, appears to be subtle. We 
did not detect a statistically significant association within the subset of ARIC study 
participants examined by cerebral MRI. A larger sample of individuals with SCT, and greater 
precision of WML measurements, may improve the ability to detect an association.  
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Table 1:  Baseline (1993-1995) demographics and clinical characteristics of African 
American participants in the ARIC brain MRI examinations 
 
Characteristic 
SCT (N=56) 
Mean ± SD or N (%) 
HbAA  (N=788) 
Mean ± SD or N (%) 
 
P-value 
Demographics    
     Age (years) 61 ± 5 62 ± 5 0.6 
     Female  28 (50%) 512 (65%) 0.02 
Medical History     
     Current smoker  15 (27%) 142 (18%) 0.1 
     Hypertension  32 (57%) 494 (63%) 0.4 
     Hypercholesterolemia 9 (16%) 162 (21%) 0.4 
     Diabetes  15 (27%) 196 (25%) 0.7 
     Coronary heart disease  1 (2%) 33 (4%) 0.7 
     Body mass index (kg/m2) 28 ± 4 30 ± 5 0.007 
 
 
Table 2:  Frequencies of WML scores at baseline MRI (1993-1995), stratified by SCT status 
Genotype Score = 0 Score = 1 Score = 2 Score = 3+ 
SCT 
 
8 (14%) 30 (54%) 10 (18%) 8 (14%) 
HbAA 
 
163 (21%) 403 (51%) 125 (16%) 97 (12%) 
*Cochrane-Maental-Haenzsel p = 0.3 
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Figure 1: Individual and cumulative prevalence odds ratios of WML associated with SCT. 
Contrasts = score of 1 or greater vs. score of 0; score of 2 or greater vs. score of 1 or 0; score 
of 3 or greater vs. score of 2, 1, or 0. All models adjusted for age, sex, hypertension, 
smoking, diabetes, and ancestry. The cumulative odds ratio is presented as a summary 
measure. 
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Abstract 
Background and Purpose:  Though frequently asymptomatic, infarctions of the small 
cerebral arteries predict adverse neurologic outcomes. The etiology of subclinical brain 
infarctions (SBI) is heterogeneous, arising from lipohyalinosis, microatheroma, and 
thrombosis. It is unknown if sickle cell trait (SCT), a genotype associated with 
hypercoagulability, is related to increased SBI risk. 
Methods:  A population-based sample of African Americans (N=828, mean age=62, 
female=64%) was prospectively imaged by cerebral MRI in 1993-1995 in the 
Atherosclerosis Risk in Communities Study (ARIC), with 477 (58%) returning for a follow 
up MRI in 2004-2006. Hemoglobin S (rs334) and hemoglobin C (rs33930165) were directly 
genotyped, and participants identified with sickle cell anemia or hemoglobin C excluded. SBI 
was detected in the cortical and subcortical regions by T1 and T2 weighted MRI, and in the 
white matter by T1 weighted imaging. Associations between SCT and the prevalence and 
progression of SBI were analyzed using logistic regression, adjusted for age, sex, smoking, 
diabetes, hypertension, total cholesterol, prevalent coronary disease, and 10 ancestral 
principal components. 
Results:  At the baseline MRI, SCT was prevalent in 55 (6.6%). SBI was detected in 14%, 
with a lower prevalence in participants with SCT (11% vs. 15%). SCT was not associated 
with prevalent SBI (POR = 0.7; 95% CI: 0.3 – 1.8), or incidence of new infarctions by the 
follow up exam (OR = 1.4; 95% CI: 0.6 – 3.1). 
Conclusion:  The associations between SCT and SBI remain elusive. Our estimates of effect 
are insignificant and demonstrate wide variability, possibly due to small sample sizes. 
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Introduction 
 Though often asymptomatic, cerebral infarctions of the small, deep, penetrating 
arteries have been shown to predict adverse neurological outcomes and future stroke104, 105.  
The etiology of subclinical brain infarction (SBI) is mixed, resulting from vascular occlusion 
by lipohyalinosis, microatheroma, and thrombosis98. Evidence of SBI is inferred from 
magnetic resonance imaging (MRI), by the presence of lacunes, small fluid filled cavities of 
necrosed cerebral tissue resulting from infarction. In observational studies, the prevalence of 
SBI appears to be correlated with age, increasing from 8% in 55-59 year olds to 23% in 65-
72 year olds71, to 43% for those over the age of 85 years100. A greater number of infarctions 
are also reported in African Americans. In a previous analysis from the ARIC baseline MRI 
examination, SBI prevalence was detected in 21% of African Americans, compared to 10% 
of white study participants71.   
 Even in pediatric populations, a high prevalence of SBI has been observed in patients 
with sickle cell anemia101, 178, 179, a Mendelian hemoglobinopathy complicated by 
hypercoagulability, microvascular occlusion, and elevated stroke risk. The carrier state, 
sickle cell trait (SCT) is prevalent in over 3 million Americans, with a heterozygous allelic 
frequency of 7-9% in African Americans and 0.2% of non-Hispanic whites180. Though 
generally considered benign, the SCT genotype has been associated with thrombosis and 
elevated factors of coagulation181. The prevalence of SBI in individuals with SCT has never 
been reported, and it is unknown if the hypercoagulability associated with SCT increases SBI 
risk. We conducted an epidemiological investigation of the prevalence and progression of 
SBI associated with SCT, using prospective MRI data from the Atherosclerosis Risk in 
Communities (ARIC) Study.   
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Methods 
  The ARIC study is a biracial, prospective, epidemiological cohort representing 4 U.S. 
areas.  A population-based sample (N= 4,270) of African Americans aged 45-65 was 
recruited with informed consent in 1987-1989 from urban, suburban, and rural areas of 
Jackson, Mississippi and Forsyth County, North Carolina.  The ARIC study includes 5 cohort 
examinations, with annual telephone surveys during interim years and ongoing surveillance 
of hospitalized events.  All study protocols were approved by the University of Mississippi 
and Forsyth County Institutional Review Boards.  
   Brain MRI was offered to a random subset of participants in 1993-1995, with a 
follow up exam offered in 2004-2006.  Standard imaging exclusions included metallic 
implants, aneurysm clips, hearing aids, cardiac pacemakers, spinal cord stimulators or other 
internal electrical devices.  Examinations were performed by certified radiographers, using 
standardized protocols and consistent imaging equipment (GE Signa 1.5 T) for both the 
baseline and follow up MRI.  Axial images were aligned parallel to the anterior commissure / 
posterior commissure line, and contiguous images were captured in 5 mm slices, from the 
vertex of the skull to the base.  T1 weighted images were acquired with a repetition time of 
500 ms and echo time of 20 ms, and T2 weighted images were captured using a 3000 ms 
repetition time and echo time of 100 ms.  All images were read by board-certified ARIC 
radiologists with subspecialty training in neuroradiology.    
 Lacunes were identified in the cortical gray matter and deep nuclear regions by signal 
hyperintensities using T1 and T2 weighted MRI, and in the white matter and brain stem by 
hypointensities in T1-weighted images. SBI diameters were measured by electronic calipers, 
using the largest dimension within the contiguous MRI slices. Because small periventricular 
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spaces are often indistinguishable from lacunes, a minimum 3 mm cut point was used. Focal, 
non-mass lesions detected within territories of vascular distributions were considered SBI 
when measuring 3-20 mm, in asymptomatic individuals with no prior stroke.  Inter- and 
intrareader agreement rates among ARIC neuroradiologists were 79% and 82%, 
respectively71. 
 For the purposes of our analysis, prevalent stroke was considered a cerebrovascular 
accident occurring prior to the baseline MRI in 1993-1995. Stroke history was determined at 
the ARIC study onset in 1987-1989, by self-reported signs and symptoms and a validated 
computer algorithm64. Incident stroke over the course of follow up was captured by hospital 
surveillance.  Hospital discharge lists for study participants with ICD-9 codes 430-438 were 
provided to the ARIC study, and stroke diagnoses were verified by physician review of the 
discharge summary, imaging reports, neurological consults, and medical history, as 
previously described60. For quality assurance, stroke diagnosis was also determined by a 
computer algorithm. Any disagreements between the physician diagnosis and computer 
algorithm were adjudicated by a second physician reviewer. Agreement rates between the 
physician reviewer and computer algorithm were 78%60.  In the majority of discordant 
diagnoses (65%), the physician adjudicator agreed with the physician reviewer, rather than 
the computer algorithm60.   
   Hemoglobin S and hemoglobin C were directly genotyped, using TaqMan high 
throughput assays, as previously described. For quality assurance, blind duplicate genotyping 
was performed in a random sample representing 5% of the total assays (kappa coefficients 
0.83 for hemoglobin S, and 0.93 for hemoglobin C). In addition to direct genotyping, high 
coverage DNA sequencing was performed. Any discrepancies were identified and 
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adjudicated by review of quality control data and re-genotyping, to yield the final 
hemoglobin S and hemoglobin C classifications. 
 Ancestry was quantified using EIGENSTRAT 5.0.1 (David Reich, open source), 
based on genomic variation characterized by the HumanExome BeadChip v1.0 (Affymetrix, 
Santa Clara, CA), as previously described171. First degree relatives were identified by PLINK 
(Shaun Purcell, http://pngu.mgh.harvard.edu/purcell/plink)172.   
 Clinical covariates were ascertained at time of the first MRI examination. Seated 
blood pressures were measured by random-zero mercury manometers. A total of 3 
measurements were made, with the average of the second and third recorded for analysis.  
Hypertension was considered a systolic blood pressure ≥ 140 mmHg, a diastolic blood 
pressure ≥ 90 mmHg, or antihypertensive medication use. Fasting cholesterol and glucose 
were assessed by ARIC central laboratories. Hypercholesterolemia was considered a total 
fasting cholesterol ≥ 6.2 mmol/L.  Diabetes was defined by either a blood glucose level ≥ 7 
mmol/L, self-reported diabetes, or use of diabetic medications. Standardized, 12-lead 
electrocardiograms were performed, and assigned a Minnesota code158 by the ARIC ECG 
Reading Center. Prevalent coronary heart disease was defined by self report, history of 
myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention; or 
electrocardiogram (ECG) suggestive of prior myocardial infarction. ECGs with Minnesota 
codes indicative of myocardial infarction (ST elevation or depression, or inverted T-waves), 
were visually inspected and adjudicated by the Minneapolis ECG Reading Center. Current 
smoking was determined by self report.   
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   A total of 937 African Americans were genotyped for hemoglobin S and hemoglobin 
C, and examined by MRI in 1993-1995.  First degree relatives (N=18), those with missing or 
inadequate genotype calls (N=3), and participants identified with hemoglobin C trait (N=24), 
hemoglobin SC disease (N=1), or sickle cell anemia (N=1) were excluded.  Additionally, 26 
participants with history of stroke were excluded, along with 36 with missing clinical 
covariates, resulting in a final study population of 828.   
Statistical Analysis 
 All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). Categorical 
variables were compared using a χ2 test, and continuous variables compared by ANOVA.  
Categorical variables with expected cell counts < 5 were analyzed using Fisher’s Exact test. 
Multivariable analyses contrasting SCT with homozygous hemoglobin A (HbAA) were 
adjusted for traditional risk factors of cerebrovascular disease (age, sex, smoking, 
hypertension, diabetes, total cholesterol, prevalent coronary disease), along with 10 ancestral 
principal components.  Prevalence odds ratios of SBI were assessed by logistic regression, 
after dichotomizing presence of infarctions at the baseline MRI. In the subset of study 
participants returning for the second MRI, progression of SBI was dichotomously defined by 
an increase in infarction number since the first MRI. The odds ratio of SBI progression 
associated with SCT was assessed by logistic regression, with adjustments for traditional risk 
factors, ancestry, and elapsed time between each MRI examination. 
 Power calculations for the prevalence odds ratio of SBI associated with SCT was 
conducted a priori, based on an assumed study population of 800, SCT prevalence of 7%, 
and SBI prevalence of 20% among the reference (HbAA) group. We hypothesized that SCT 
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would be associated with greater prevalence of SBI, and expected 80% power to detect a 
prevalence odds ratio of 2.3, with significance at the α = 0.05 level (2-sided).   
Results 
   Out of 828 African Americans, SCT was prevalent in 55 (6.6%) participating in the 
baseline MRI examination.  The mean age at the study onset was 62 years, and 64% were 
women. Study participants with SCT were more often men (51% vs. 35%; p=0.02) and less 
obese (28 kg/m2 vs. 30 kg/m2 BMI; p=0.006), with a slightly greater prevalence of current 
smoking.  (Table 1).   
   At the baseline MRI, SBI was detected in 14%, with a greater prevalence in 
participants with the HbAA genotype (15% vs. 11%; p=0.4). The number of detected 
infarctions ranged from 0 to 5, however, the majority identified with SBI (77%) had a single 
infarction. When categorized into groups of zero, 1, and more than 1 infarction, individuals 
with SCT had a lower prevalence of single infarctions, but similar prevalence of multiple 
infarctions (Table 2).  
   In multivariable regression analysis controlling for age, sex, smoking, hypertension, 
diabetes, total cholesterol, prevalent coronary disease, and ancestry, SCT was not associated 
with prevalent SBI at the baseline MRI (POR = 0.7; 95% CI: 0.3 – 1.8), as shown in Table 3. 
   Of the 828 study participants examined by brain MRI in 1993-1995, 477 (58%) 
returned for the follow up MRI in 2004-2006. Within this subset, 36 (7.5%) were identified 
with SCT.  The mean elapsed time between the baseline and follow up MRI examinations 
was 10.8 ± 0.9 years, which did not differ by SCT status (p=0.8). An increase in SBI number 
was detected in 108 participants (23%), with a higher frequency of progression in those with 
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SCT (28% vs. 22%, p=0.4). Of those classified with SBI progression, the mean increase in 
infarction number was 1.4 ± 0.7, which was similar among HbAA and SCT genotypes 
(p=0.6). In multivariable regression analysis controlling for age, sex, smoking, hypertension, 
diabetes, total cholesterol, prevalent coronary disease, ancestry, and elapsed time between 
MRI examinations, SCT was not significantly associated new infarctions (OR = 1.4; 95% CI: 
0.6 – 3.1).  Additional analyses are shown in Appendix II. 
Discussion 
 This is the first epidemiological study to examine SCT and SBI prevalence and 
progression in the general population of African Americans. Contrary to our expectation, 
SCT was not associated with a higher prevalence of SBI. However, the estimate was widely 
variable, making it inconclusive. Our initial power calculation assumed a higher risk 
associated with SCT, and we expected 80% power to detect an SBI odds ratio of 2.3. When 
examined as a protective exposure, we would have had 80% power to detect an SBI odds 
ratio of 0.3. Our analysis was therefore underpowered to detect the observed odds ratio of 0.7 
(0.3 – 1.8). In the subset of study participants returning for the follow up MRI, we observed a 
40% higher risk of SBI progression in those with SCT; however, the estimate was 
insignificant and limited by the small sample size.  
SBI is commonly observed in elderly populations, and though asymptomatic, has 
been associated with subtle neurological deficits and future cognitive decline. In the 
Rotterdam Scan Study, which prospectively imaged 1015 stroke-free, elderly subjects by 
MRI, those with SBI were found to have a steeper decline in cognitive function, and more 
than twice the risk of developing dementia or Alzheimer’s disease104. SBI has also been 
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associated with future stroke. In the Cardiovascular Health Study, examining 3,324 stroke-
free elderly subjects by cerebral MRI, SBI was correlated with a 50% higher stroke risk over 
a 4 year follow up period105. Progression of SBI has also been associated with adverse 
neurological outcomes, as well. In a subset of the Cardiovascular Health Study undergoing 
cerebral MRI with follow up imaging 5 years later, new infarctions were correlated with 
decreased scores on both the Modified Mini-Mental State Examination and the Digit-Symbol 
Substitution test103.   
Brain autopsies identifying the source of SBI are infrequently done, as this requires 
uninterrupted serial sections of the basal ganglia, tracing the infarcted area proximally until 
an occlusion is found98. However, from the few published autopsy reports, the etiology of 
SBI appears to be heterogeneous, arising from obstructions of the small penetrating arteries 
by embolic particles of atheroma, or blockages due to lipohyalinosis, a hypertrophic adaption 
to hypertension that eventually occludes the arterial lumen61.  In the absence of identifiable 
obstructions by post-mortem examination, thrombus is suspected, as blood clots lyse and 
disappear within days of an embolic event98. The thrombotic etiology of SBI is supported by 
a case-control analysis from the ARIC study, comparing coagulation factors in 196 SBI cases 
and 214 age- race- and sex matched controls without SBI99. The odds of SBI were nearly 
doubled when contrasting the highest with lowest tertiles of d-dimer and von Willebrand 
factor, suggesting an association with coagulation.  
Hypercoagulability, thrombosis, and microvascular occlusion are known 
complications of sickle cell anemia, a Mendelian hemoglobinopathy characterized by 
misshapen red blood cells, vaso-occlusive crisis, acute chest syndrome, and pain. Even in 
childhood, SBI is commonly observed in patients with sickle cell anemia, prevalent in 27% 
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of patients under the age of 6178, and 37% under the age of 14179. Though unaccompanied by 
neurological deficits, SBI has been associated with poor academic achievement in children 
with sickle cell anemia, and with future stroke101.  The prevalence of SBI in adults with 
sickle cell anemia is less well established; however, in a cross sectional study of 149 
participants with a mean age of 32 years, lacunes were detected in 13% of patients with 
sickle cell anemia, compared to 2% of age, sex, and education matched African American 
controls102. To date, no publications have examined heterozygous SCT as a genetic risk 
factor for SBI. 
Even in heterozygous carriers, hemoglobin S is associated with hypercoagulability.  
Under conditions of exertion, dehydration, and high altitude, SCT erythrocytes are known to 
sickle and polymerize11, 27. The sickling deformation exposes phosphatidylserine on the cell 
membrane surface, facilitating the assembly of coagulation enzymatic complexes29. 
Laboratory assays of healthy individuals with SCT show elevated markers of coagulation 
(prothrombin fragment 1+2, thrombin-antithrombin complex, and d-dimer)26, and 
epidemiological studies report twice the risk of pulmonary embolism and venous 
thrombosis33, 34.  Though seemingly plausible, it is unknown if the hypercoagulability and 
greater prevalence of thromboembolism observed in individuals with SCT conveys a 
heightened risk of SBI. 
  In conclusion, additional research is required to draw conclusions relating SCT to 
SBI. Our estimates were too variable to be definitive, and the analysis was underpowered to 
detect even moderate effects.  
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Table 1:  Baseline (1993-1995) demographics and clinical characteristics of African 
American participants in the ARIC brain MRI examinations 
 
Characteristic 
SCT (N=55) 
Mean ± SD or N (%) 
HbAA  (N=773) 
Mean ± SD or N (%) 
 
P-value 
Demographics    
     Age (years) 61 ± 5 62 ± 5 0.6 
     Female  27 (49%) 512 (65%) 0.02 
Medical History     
     Current smoker  15 (27%) 139 (18%) 0.09 
     Hypertension  31 (56%) 484 (63%) 0.4 
     Hypercholesterolemia 8 (15%) 160 (21%) 0.3 
     Diabetes  15 (27%) 192 (25%) 0.7 
     Coronary heart disease  1 (2%) 33 (4%) 0.7 
     Body mass index (kg/m2) 28 ± 4 30 ± 5 0.006 
 
Table 2:  Frequencies of SBI counts at baseline MRI (1993-1995), stratified by SCT status 
Genotype Normal 
Count = 0 
Mild 
Count = 1 
Moderate 
Count > 1 
SCT 
 
49 (89%) 3 (5%) 3 (5%) 
HbAA 
 
659 (85%) 74 (10%) 40 (5%) 
*Cochrane-Maental-Haenzsel p = 0.3 
 
Table 3:  Multivariable regression models contrasting SCT with HbAA 
Model Outcome and Adjustments Odds Ratio (95% CI) 
Prevalent SBI at baseline MRI  
     Demographics 0.72 (0.30 – 1.76) 
     Demographics, clinical covariates 0.69 (0.28 – 1.70) 
     Demographics, clinical covariates, ancestry 0.71 (0.28 – 1.78) 
Incident SBI at follow up MRI (≥1 new infarct)  
     Demographics, elapsed time 1.35 (0.62 – 2.95) 
     Demographics, clinical covariates, elapsed time 1.42 (0.64 – 3.13) 
     Demographics, clinical covariates, ancestry, elapsed time 1.40 (0.63 – 3.12) 
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DISCUSSION 
1.   Introduction   
   This is the first epidemiological study to examine associations between SCT and 
cerebral small vessel disease.  In a previous analysis from the ARIC study, an increased risk 
of stroke was observed in participants with SCT, compared to those with homozygous 
hemoglobin A.  The pathophysiology of stroke in SCT carriers is unclear, however.  Though 
not considered a hematological disorder, the SCT phenotype is nonetheless associated with 
hypercoagulability, vasculopathy, and possibly hypoperfusion.  In the general population, 
future stroke has been predicted by cerebral small vessel disease.  Subclinical brain 
infarctions, blockages of the small cerebral vessels by atheroma, lipohyalinosis, and 
thrombus, are associated with hypercoagulability.  Thus, it seems biologically plausible that 
individuals with SCT would have heightened risk of SBI, a potential etiologic pathway to 
stroke.  In addition, white matter lesions, often indicative of axon demyelination and 
hypoperfusion, have been observed with greater frequency in pediatric SCT carriers.  
However, these findings have yet to be replicated in a large, epidemiological study. 
2.  Key Findings 
   In the present study, we observed no statistically significant associations between 
SCT and cerebral small vessel disease.  There was a trend for greater WML prevalence and 
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severity among those with SCT, as well as a higher 11-year incidence of SBI; however, the 
estimates were imprecise and inconclusive.   
   Associations between SCT and WML prevalence were examined by ordinal 
regression.  First, the odds of having a WML score of 1, 2, or ≥ 3 were contrasted with 
having a score of 0. Next, the odds of a WML score of ≥ 2 were contrasted to a score of 0 or 
1. Finally, the odds of a WML ≥ 3 were contrasted with a score of 0, 1, or 2.  The advantage 
of this analysis is that it minimizes cut-point bias, which may result from arbitrarily assigned 
WML prevalence definitions.  Because none of these contrasts significantly differed from 
each other and the assumptions of proportional odds were upheld, the cumulative logit was 
exponentiated to estimate the summary odds ratio of WML associated with SCT. We 
observed a 20% greater odds of WML associated with SCT, which was non-significant.    
   The association between SCT and WML severity was assessed by linear regression.  
A multiple regression model was used, to examine the mean difference in severity scores 
between individuals with SCT and HbAA.  Among those with SCT, the mean WML score 
was 0.2 points higher than those with HbAA; however, our analysis was only powered to 
detect a mean difference of 0.4 or greater.  The progression of WML by the follow-up MRI 
was examined by 2 methods.  First, a linear model was used, analyzing the mean increase in 
WML score associated with SCT.  We also analyzed progression using a logistic model, by 
defining progression as a longitudinal increase in severity score of at least 2 points.  Though 
more conservative, we chose at least 2 points over 1 point to avoid spurious progression, 
which may simply reflect inaccuracies of the qualitative scoring method.  However, the 
analyses of WML progression were non-significant, regardless of methodological technique.  
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   Baseline prevalence and longitudinal progression of SBI were both analyzed by 
logistic regression.  SBI prevalence was considered one or more infarction detected by MRI, 
and progression of SBI was defined by an increase in number of infarctions between the first 
and second MRI examinations.  At the baseline MRI, there were only 6 cases of SBI among 
the 56 SCT carriers, which severely limited the analysis.  By the follow up exam, the SBI 
prevalence among those with SCT had increased from 11% to 31%; however, only 36 
individuals with SCT returned for the second MRI.  Compared to HbAA individuals, those 
with the SCT genotype had 30% lower odds of SBI at the baseline MRI.  The confidence 
intervals were implausibly broad though, and the estimate was non-significant.  By the 
follow up exam, participants with SCT had a 40% higher odds of newly detected SBI lesions.  
Again, the confidence intervals were broad and this analysis was non-significant and 
inconclusive. 
   With a sample size of only 56 SCT carriers imaged by cerebral MRI, analyses of 
modification by traditional stroke risk factors, sickle haplotype, co-inherited 
hemoglobinopathies, or stroke candidate genes did not appear feasible.  However, we 
discovered that most potential genetic modifiers were highly imputable using the Affymetrix 
6.0 microarray and 1000 Genomes reference panel.  SNPs from candidate genes associated 
with stroke in children with sickle cell anemia, ADCY9, BMP6, CSF2, ECE1, ERG, MET, 
SELP, TEK, TGFBR3, and TNF-α, imputed well, each with a quality score greater than .90.  
Stroke candidate genes with genome-wide significance, HDAC9, PITX2, and NINJ2, also 
imputed with high quality.  SNPs from two genes influencing gamma globin and fetal 
hemoglobin concentrations, HBSIL-MYB and BCL11A, imputed with high quality.  The SNP 
for the most common alpha-thalassemia deletion in African Americans was not imputable to 
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the 1000 genomes panel, using either the Affymetrix array or Exome chip.  Likewise, the 
SNP for the Senegal sickle haplotype was not imputable; however, several proxy SNPs 
identified by PLINK imputed with very high quality.  This preliminary analysis provides 
proof of concept that potential genetic modification of association between SCT and 
cerebrovascular disease could be assessed, provided an adequately large sample size.  
3.  Public Health Implications 
   Since 2006, all 50 of the United States have mandated neonatal screenings for sickle 
hemoglobinopathies.  Consequently, SCT status is now documented in the medical record of 
younger African Americans.  With a heterogeneous allelic frequency of 7-9% in African 
Americans and 0.2% in non-Hispanic whites, SCT is estimated to affect over 3 million 
Americans.  Increasingly, research suggests SCT may not be entirely benign, raising the 
possibility that the SCT genotype may be used to target high risk individuals for potential 
therapeutic interventions.  However, at the current state of science, potential interventions – 
which may be behavioral, environmental, pharmacological, or genetic; and the ideal time to 
initiate them, are unknown. 
4.  Strengths and Limitations 
   The ARIC study includes a large sample of older African Americans with SCT 
identified by direct genotyping.  A subset of study participants was randomly selected for 
cerebral MRI examination, with images read by trained neuroradiologists using standardized 
criteria.  Despite these strengths, we were unable to conclusively examine the associations 
between SCT and cerebral small vessel disease.  Of the 844 African Americans undergoing 
cerebral MRI, only 56 were SCT carriers.  As a result, we did not have the statistical power 
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to detect even moderately higher risks of cerebral small vessel disease in those with SCT.  
The assessment of WML was additionally hindered by the qualitative severity scores, which 
were subject to measurement error and only fair inter-reader and intra-reader reliability.  
5.  Future Directions 
   Our analysis of SCT and cerebral small vessel disease is inconclusive.  To gain a 
more definitive understanding of the cerebrovascular pathophysiology associated with SCT, 
an analysis with adequate statistical power is required.  The statistical power would be 
improved with a larger sample of SCT carriers, or better precision of the image 
measurements.  In order to augment the sample size, collaborations with other cohort studies 
examining African Americans by cerebral MRI could be forged.  However, data 
harmonization is a potential concern, if SCT genotypes are identified using differing 
methods, or brain MRI is performed by scanners with different image resolution.   
   MRI scanner resolution has improved dramatically over the past 20 years, and by the 
time the ARIC cohort was examined at visit 5 (2011 – 2013), scanners had been upgraded 
from 1.5 to 3.0 Tesla magnets.  The newer scanners not only have better resolution, but the 
capability to measure 3D volumes, obviating the need to score WML severity with a 
qualitative scale.  Diffusion tensor imaging, another feature available in the visit 5 MRI, has 
been shown to enhance detection of small vessel disease and white matter abnormalities as 
well, which may improve precision of the outcome.  Though currently unmeasured in the 
ARIC study, cerebral artery tortuosity and dolichoectasia could be assessed, using the visit 5 
MRI images.  This has previously been measured in other cohort studies, using custom-built 
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image analysis software.  The association between SCT and brain volumes, or micro-
hemorrhage could also be analyzed from the visit 5 MRI.       
   In the future, the effect of genetic modification on the association between SCT and 
cerebrovascular disease could be assessed as well.  This would obviously require a much 
larger sample size than currently available in the ARIC study, but could be potentially 
interesting.  Alpha thalassemia deletions are highly prevalent (30%) in African Americans, 
and known to modify the amount of hemoglobin S produced when co-inherited with the 
sickle mutation.  It would be reasonable to hypothesize that alpha thalassemia would 
influence the associations between SCT and cerebrovascular disease.  Modification by stroke 
candidate genes could also be an interesting area of further research.   
   Influences from the environment, lifestyle, and behavior affecting SCT and 
cerebrovascular disease risk could also be examined.  This, too, would require a much larger 
sample size than currently available, but could be enormously beneficial if shown to 
influence associations between SCT and cerebrovascular disease.  Unlike genetic modifiers, 
the environmental, lifestyle, and behavioral factors are largely modifiable.  If an exposure 
such as smoking or hormone replacement therapy were shown to interact with SCT to cause 
heightened coagulation and cerebrovascular disease, strategies could be developed to 
mitigate risk.  It is already known that high altitude, dehydration, and heavy exertion cause 
erythrocyte sickling in SCT carriers, and an assessment of how these exposures may 
influence an individual with SCT’s likelihood of developing cerebrovascular disease could 
also be assessed. 
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APPENDIX 1 
Figure 1aI. Determination of final study population 
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Figure 2aI. Distribution of white matter scores at baseline MRI (1993-1995) 
 
 
The majority of study participants (80%) were identified with WML at the baseline MRI. 
Most (52%) had a mild presentation, classified as a WML score of 1. The distribution of 
scores was unimodal and skewed right (skewness = 1.8), with a kurtosis value of 4.3 and 
significant departure from normality (Kolmogov-Smirnov test p < 0.01).  
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Figure 3aI. Baseline MRI (1993-1995) white matter score distributions, stratified by SCT 
status. 
 
 
Table 1aI. Distribution of baseline WML scores, stratified by SCT status 
WML Scores (0-8) 
 0 1 2 3 4 5 6 7 8 
SCT 8 
(14%) 
30 
(54%) 
10 
(18%) 
2 
(4%) 
1 
(2%) 
4 
(7%) 
1 
(2%) 
 
0 0 
HbAA 163 
(21%) 
403 
(51%) 
125 
(16%) 
53 
(7%) 
18 
(2%) 
16 
(2%) 
7 
(1%) 
2 
(0.3%) 
1 
(0.1%) 
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Figure 4aI. Individual and cumulative prevalence odds ratios of WML associated with SCT. 
Contrasts = score of 1 or greater vs. score of 0; score of 2 or greater vs. score of 1 or 0; score 
of 3 or greater vs. score of 2, 1, or 0. All models adjusted for age, sex, hypertension, 
smoking, diabetes, and ancestry. 
 
 
Proportional odds test: χ2 = 39.9 (32 degrees of freedom); p=0.2. There is insufficient 
evidence to reject the null hypothesis, which assumes the increment to the log odds 
associated with SCT is equivalent for each contrast. The cumulative prevalence odds ratio is 
therefore reported as a summary estimate. 
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Table 2a. Linear regression models analyzing absolute and relative increment to baseline 
WML score associated with SCT.  
 
Model Beta p-value Interpretation 
WML mean score   SCT is insignificantly associated 
with a mean WML score that is 0.2 
points higher than those with 
HbAA 
     Crude 0.2 0.2 
     Demographics 0.2 0.1 
     Demographics, Covariates, Ancestry 0.2 0.2 
Log of WML mean score   SCT is insignificantly associated 
with a mean WML score that is 9% 
higher, attenuating to a score 7% 
higher after full adjustments. 
     Crude 0.09 0.2 
     Demographics 0.09 0.1 
     Demographics, Covariates, Ancestry 0.07 0.2 
*Demographics = age, sex 
  Covariates = hypertension, diabetes, smoking 
 
Justification for the absolute rather than relative model: 
Linear models assume homoscedasticity and a linear relationship between the dependent 
variable and any continuous predictor variables. WML is a non-normally distributed variable; 
however, its distribution of residuals approximates a normal distribution reasonably well, 
demonstrating near-homoscedasticity (Figure 5a). The continuous variables (age and the 10 
principal components) demonstrate linear relationships with WML score, shown by the 
nearly equal distribution of residuals both above and below the reference line (Figure 6a). 
Because risk is best measured on the additive scale, and the linear model demonstrates 
reasonable fit, the linear model without log transformation of the WML variable is preferred. 
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Figure 5aI. Near-homoscedastic distribution of WML residuals 
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Figure 6aI. Residuals for continuous variables (age and 10 principal components) 
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Table 3aI. Demographics and baseline clinical characteristics of study participants examined 
by cerebral MRI in 1993-1995, who either did or did not return for follow up imaging in 
2004-2006. 
 
 
Baseline Characteristics 
 
Follow-up MRI  
(N=470) 
Mean ± SD or N (%) 
No Follow-up MRI  
(N=377) 
Mean ± SD or N (%) 
 
P-value 
Demographics    
     Age (years) 61 ± 4 62 ± 5 0.0001 
     Female  297 (63%) 245 (65%) 0.6 
Medical History  
     Sickle cell trait 
 
36 (7.7%) 
 
20 (5.3%) 
 
0.2 
     Current smoker  74 (16%) 85 (23%) 0.01 
     Hypertension  
     Systolic blood pressure 
     Diastolic blood pressure 
271 (58%) 
131 ± 20 
75 ± 10 
257 (68%) 
136 ± 22 
75 ± 11 
0.002 
0.0007 
0.9 
     Total cholesterol 208 ± 41 211 ± 39 0.3 
     Diabetes  98 (21%) 113 (30%) 0.002 
     Coronary heart disease  8 (2%) 26 (7%) 0.0001 
     Body mass index (kg/m2) 
Magnetic Resonance Imaging 
     White matter lesions 
     Mean WML score 
29 ± 5 
 
360 (77%) 
1.1 ± 1.0 
30 ± 6 
 
315 (84%) 
1.6 ± 1.4 
0.05 
 
0.01 
<0.0001 
 
Study participants returning for the follow up MRI in 2004-2006 had fewer comorbid 
conditions at the baseline MRI in 1993-1995 than those not returning for the follow-up exam. 
In addition, white matter lesions detected at the baseline MRI were both less prevalent and 
less severe in those returning for follow-up imaging. The remaining population examined by 
cerebral MRI in 2004-2006 was likely influenced by selective survival. 
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Figure 7aI. Distribution of change in WML score between baseline (1993-1995) and follow-
up (2004-2006) cerebral MRI examinations. 
 
 
An increase in the WML severity score was observed in the majority (71%) of participants; 
however no change was observed in 27%, and a decrease in severity score was detected in 
2%.  
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Figure 8aI.  Distributions of change in WML score between baseline (1993-1995) and 
follow-up (2004-2006) cerebral MRI examinations, stratified by SCT status. 
 
 
Table 4aI. Distribution of WML score change, stratified by SCT status 
 
 -2 -1 0 1 2 3 4 5 
SCT 0 
 
1 
(3%) 
12 
(35%) 
12 
(35%) 
8 
(25%) 
1 
(3%) 
 
0 
 
0 
HbAA 1 
(0.2%) 
6 
(1%) 
115 
(27%) 
165 
(39%) 
88 
(21%) 
32 
(8%) 
10 
(2%) 
5 
(1%) 
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APPENDIX II 
Due to the small number of subclinical infarctions (n=6) observed in the 56 SCT cases 
imaged by cerebral MRI at the baseline examination, it was suggested that prevalence 
estimates should be examined at the follow up MRI exam.  Because SBI is strongly 
associated with age, it was assumed that the greater number of lesions (in both individuals 
with SCT and HbAA) by the follow up examination would enhance the statistical precision 
and power to detect an association.  Indeed, by the follow up examination, the SBI 
prevalence had increased in both groups (Table 1aII). 
Table 1aII:  Frequencies of SBI counts at baseline (1993-1995) and follow up (2004-2006) 
MRI examinations, stratified by SCT status 
Genotype Normal 
SBI Count = 0 
Mild 
SBI Count = 1 
Moderate 
SBI Count > 1 
Total 
SBI Count 
MRI Exam 1*     
     SCT 49 (89%) 3 (5%) 3 (5%) 6 (11%) 
     HbAA 659 (85%) 74 (10%) 40 (5%) 114 (15%) 
MRI Exam 2†     
     SCT 24 (69%) 8 (23%) 3 (9%) 11 (31%) 
     HbAA 315 (74%) 78 (18%) 30 (7%) 108 (26%) 
*Cochrane-Maental-Haenzsel p = 0.6 
†Cochrane-Maental-Haenzsel p = 0.5 
 
The prevalence of SBI in SCT carriers increased from 11% to 31% by the follow up 
examination, and from 15% to 26% in those with the HbAA genotype.  However, the study 
population attending the follow up MRI was strikingly different from those either choosing 
not to, or unable, to participate in the follow up MRI (Table 2aII). 
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Table 2aII. Demographics and baseline clinical characteristics of study participants 
examined by cerebral MRI in 1993-1995, who either did or did not return for follow up 
imaging in 2004-2006. 
Baseline Characteristics Follow-up MRI 
(N=470) 
Mean ± SD or N (%) 
No Follow-up MRI  
(N=377) 
Mean ± SD or N (%) 
                  
P-value 
Demographics    
     Age (years) 61 ± 4 62 ± 5 0.0001 
     Female  297 (63%) 245 (65%) 0.6 
Medical History  
     Sickle cell trait 
 
36 (7.7%) 
 
20 (5.3%) 
 
0.2 
     Current smoker  74 (16%) 85 (23%) 0.01 
     Hypertension  
     Systolic blood pressure 
     Diastolic blood pressure 
271 (58%) 
131 ± 20 
75 ± 10 
257 (68%) 
136 ± 22 
75 ± 11 
0.002 
0.0007 
0.9 
     Total cholesterol 208 ± 41 211 ± 39 0.3 
     Diabetes  98 (21%) 113 (30%) 0.002 
     Coronary heart disease  8 (2%) 26 (7%) 0.0001 
 
Moreover, the projected power to detect an association between SBI and SCT was not 
improved by the follow up, due to the overall decreased sample of study participants imaged 
at the second MRI (Figures 1aII and 2aII). 
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Figure 1aII: Power curves for odds ratios of SBI prevalence among those with SCT, 
compared to study participants with HbAA, at the first MRI:  Assumed sample size = 800, 
assumed prevalence of SCT = 7%, assumed reference prevalence of SBI = 20%. 
    
We expected 80% power to detect an odds ratio of 2.3 (if SCT is associated with increased 
risk of SBI), or an odds ratio of 0.3 (if SCT is associated with decreased risk of SBI). 
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Figure 2aII: Power curves for odds ratios of SBI prevalence among those with SCT, 
compared to study participants with HbAA, at the follow-up MRI:  Assumed sample size = 
450, assumed prevalence of SCT = 7%, assumed reference prevalence of SBI = 30%. 
 
We expected 80% power to detect an odds ratio of 3.0 (if SCT is associated with increased 
risk of SBI), or an odds ratio of 0.2 (if SCT is associated with decreased risk of SBI). 
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Based on the power calculations, the insignificant prevalence odds ratios estimates for the 
baseline and follow-up MRI examinations were unsurprising (Table 3aII). 
 
Table 3aII:  Multivariable regression models of prevalent SBI, contrasting SCT with HbAA 
at the baseline (1993-1995) and follow-up (2004-2006) MRI examinations 
Model Outcome and Adjustments Odds Ratio (95% CI) 
Prevalent SBI at baseline MRI  
     Demographics 0.72 (0.30 – 1.76) 
     Demographics, clinical covariates 0.69 (0.28 – 1.70) 
     Demographics, clinical covariates, ancestry 0.71 (0.28 – 1.78) 
Prevalent SBI at follow-up MRI  
     Demographics 1.35 (0.63 – 2.87) 
     Demographics, clinical covariates 1.36 (0.63 – 2.93) 
     Demographics, clinical covariates, ancestry 1.40 (0.64 – 3.05) 
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